U.S. patent application number 12/329218 was filed with the patent office on 2010-01-07 for novel collagen-like protein clac, precursor thereof and genes encoding the same.
This patent application is currently assigned to EISAI R & D MANAGEMENT CO., LTD.. Invention is credited to Tadafumi HASHIMOTO, Takeshi IWATSUBO, Yasuo NAGAI.
Application Number | 20100004433 12/329218 |
Document ID | / |
Family ID | 11735679 |
Filed Date | 2010-01-07 |
United States Patent
Application |
20100004433 |
Kind Code |
A1 |
IWATSUBO; Takeshi ; et
al. |
January 7, 2010 |
NOVEL COLLAGEN-LIKE PROTEIN CLAC, PRECURSOR THEREOF AND GENES
ENCODING THE SAME
Abstract
A novel human collagen-like protein CLAC occurring in brain
amyloid and its precursor CLAC-P; genes encoding the same; cDNA of
mouse CLAC-P and its deduced amino acid sequence; antibodies
specific to these proteins; and methods of diagnosing treating and
preventing Alzheimer's disease by using the same.
Inventors: |
IWATSUBO; Takeshi; (Tokyo,
JP) ; HASHIMOTO; Tadafumi; (Tokyo, JP) ;
NAGAI; Yasuo; ( Osaka, JP) |
Correspondence
Address: |
Studebaker & Brackett PC
One Fountain Square, 11911 Freedom Drive, Suite 750
Reston
VA
20190
US
|
Assignee: |
EISAI R & D MANAGEMENT CO.,
LTD.
Tokyo
JP
Takeshi IWATSUBO
Tokyo
JP
|
Family ID: |
11735679 |
Appl. No.: |
12/329218 |
Filed: |
December 5, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10203561 |
Aug 12, 2002 |
7514542 |
|
|
PCT/JP01/01014 |
Feb 14, 2001 |
|
|
|
12329218 |
|
|
|
|
Current U.S.
Class: |
536/23.5 |
Current CPC
Class: |
A01K 2217/05 20130101;
A61P 25/28 20180101; A61K 38/00 20130101; C07K 14/4711 20130101;
C07K 14/78 20130101 |
Class at
Publication: |
536/23.5 |
International
Class: |
C07H 21/04 20060101
C07H021/04 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 14, 2000 |
JP |
PCT/JP00/00788 |
Claims
1-41. (canceled)
42. An isolated or genetically-engineered polynucleotide comprising
a nucleotide sequence encoding amino acid 113 to amino acid 654 of
SEQ ID NO: 2 in which one or more amino acids located at amino acid
positions 141, 142, 143, 144, 145, 146, 589, 590, 591, 592, 593,
594, 595, 596, or 597 are deleted or substituted.
Description
[0001] This application is a divisional application of U.S.
application Ser. No. 10/203,561, filed April 2002.
[0002] The present invention relates to a human-type collagen-like
protein (CLAC) and a precursor thereof (CLAC-P) in amyloid that
accumulates in Alzheimer's brain and forms senile plaques; and
genes encoding them. Further the present invention relates to a
cDNA and an amino acid sequences of mouse-type CLAC-P. The present
invention also relates to development of: a method for treating of
Alzheimer's disease by inhibiting a mechanism of accumulation of
amyloid proteins, a method for treating Alzheimer's disease by
inhibiting cell injury, and a method for diagnosing Alzheimer's
disease.
BACKGROUND OF THE INVENTION
[0003] Alzheimer's disease is a dementing neurodegenerative disease
characterized by formation of senile plaques and neurofibrillary
degeneration as well as degeneration of neurons. Senile plaques
that are most characteristic of this disease are lesions composed
mainly of amyloid-beta peptide (A.beta.) derived from beta-amyloid
presursor protein (.beta.APP) (Biochem Biopys Res Commun 122, 1131
(1984)), with apolipoprotein E (Brain Res 541, 163 (1984)) and a
complement component C1q (Acta Neuropathol 57, 239 (1982)), etc
being deposited. A.beta. aggregates by itself, and formation of
amyloid fiber is promoted by actions of non-A.beta. amyloid
components such as apolipoprotein E (Nature 372, 92 (1994)) and C1q
(J Neurosci Res 46, 58 (1996)) as above described. A.beta.
consisting of 40-42 amino acids is secreted from various cells
including neurons, and it is not toxic to cells at a normal
concentration. However at a higher concentration, A.beta.
aggregates and becomes toxic to neurons (Science 250, 279 (1990)).
In this process, it is known that several molecules such as RAGE
(Nature 382, 685 (1996)) and scavenger receptor A (Nature 382, 716
(1996)) are present on the cell surface and act as receptors for
aggregated A.beta.. It seems that aggregation, accumulation, and
toxicity to cells of amyloid are very important in neuronal
degeneration process of Alzheimer's disease; therefore, inhibition
of these processes will be an effective therapeutic method for
Alzheimer's disease.
[0004] Accumulation of A.beta. as amyloid is very characteristic of
Alzheimer's disease, however it is being clarified that only
accumulation of A.beta. is not sufficient for toxicity to neurons
as well as for the development of Alzheimer's disease (J. neurosci.
17, 7053 (1997)). On the other hand, as inferred from the fact that
genetic polymorphism of proteins such as apolipoprotein E which
promotes accumulation process of senile plaque amyloid serves as a
risk factor for development of Alzheimer's disease (Science 261,
921 (1993)). It has been noted that unknown proteinaceous
components in amyloid can greatly influence the accumulation and
neuronal injury by amyloid; however the responsible components have
not been identified yet.
SUMMARY OF THE INVENTION
[0005] Taking circumstances above mentioned into consideration, the
inventors produced mouse monoclonal antibodies to an amyloid
fraction extracted from of a brain of a patient with Alzheimer's
disease, and surprisingly found a monoclonal antibody among these
antibodies which selectively stains senile plaque amyloid and
biochemically recognizes a novel protein of 50 to 100
kilodaltons.
[0006] Further the inventors studied the amyloid deposits on the
basis of these findings, and found a novel human collagen-like
Alzheimer amyloid plaque component (CLAC), and succeeded in
obtaining entire structure of CLAC and cloning a novel gene
encoding entire CLAC and a precursor thereof (CLAC-P). Further the
inventors determined cDNA sequence of mouse-type CLAC-P, and
deduced the amino acid sequence.
[0007] The present invention relates to:
[0008] (1) CLAC DNA comprising a nucleotide sequence of nucleotide
868 to nucleotide 2493 shown in SEQ ID NO: 1,
[0009] (2) CLAC comprising an amino acid sequence of amino acid 113
to amino acid 654 shown in SEQ ID NO: 2,
[0010] (3) A DNA encoding a protein in which one or plural amino
acids are inserted into, deleted from, or substituted in CLAC
defined in (2), said encoded protein having following
properties:
[0011] (a) accumulating in senile plaque amyloid component of
Alzheimer's disease, and
[0012] (b) having a function of promoting aggregation of
A.beta.,
[0013] (4) A DNA which hybridizes to the DNA defined in (1) under a
stringent condition, and encodes a protein having the following
properties:
[0014] (a) accumulating in senile plaque amyloid component of
Alzheimer's disease, and
[0015] (b) having a function of promoting aggregation of
A.beta.,
[0016] (5) A protein encoded by a DNA defined in (3) or (4),
[0017] (6) CLAC-P DNA comprising a nucleotide sequence of
nucleotide 532 to nucleotide 2493 shown in SEQ ID NO: 1,
[0018] (7) CLAC-P comprising an amino acid sequence shown in SEQ ID
NO: 2,
[0019] (8) A DNA encoding a protein in which one or plural amino
acids are inserted into, deleted from, or substituted in CLAC-P
defined in (7), said encoded protein functioning as an A.beta.
receptor on cell surface,
[0020] (9) A DNA which hybridizes to a DNA defined in (6) under a
stringent condition and encodes a protein functioning as an A.beta.
receptor on cell surface,
[0021] (10) A protein encoded by a DNA defined in (8) or (9),
[0022] (11) A protein defined in (10) in which one or more amino
acids are deleted from or substituted in a region of amino acid 141
to 146, or amino acid 589 to 597 shown in SEQ ID NO: 2,
[0023] (12) An expression vector containing a DNA defined in any
one of (1), (3) and (4),
[0024] (13) A transformant transformed by a vector defined in
(12),
[0025] (14) A method for producing a recombinant protein, which
comprises culturing a transformant defined in (13) under a
condition enabling an expression vector defined in (12) to be
expressed,
[0026] (15) An expression vector containing a DNA defined in any
one of (6), (8) and (9),
[0027] (16) A transformant transformed by a vector defined in
(15),
[0028] (17) A method for producing a recombinant protein, which
comprises culturing a transformant defined in (16) under a
condition enabling an expression vector defined in (15) to be
expressed,
[0029] (18) A transformant deposited to International Patent
Organism Depositary, National Institute of Advanced Industrial
Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi
1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) under accession
No. FERM BP-7438,
[0030] (19) CLAC-P gene contained in a transformant defined in
(18),
[0031] (20) A method for producing a recombinant protein, which
comprises culturing a transformant defined in (18) under a
condition enabling a vector contained therein that contains CLAC-P
gene to be expressed,
[0032] (21) An antibody which specifically binds to a protein
defined in (2) or (5),
[0033] (22) An antibody defined in (21) which is a monoclonal
antibody 9D2,
[0034] (23) A method for screening an inhibitor of CLAC activity,
which comprises using a protein defined in (2) or (5).
[0035] (24) An inhibitor of CLAC activity obtainable by a screening
method defined in (23),
[0036] (25) A method for detecting CLAC, which comprises using an
antibody defined in (21),
[0037] (26) A method for treating of, delaying progress of, or
preventing Alzheimer's disease, which comprises using an antibody
defined in (21) or an inhibitor of CLAC activity defined in
(24),
[0038] (27) A method defined in (25), in which the antibody is
monoclonal antibody 9D2,
[0039] (28) A method defined in (26), in which the antibody is
monoclonal antibody 9D2,
[0040] (29) A method for purifying CLAC, which comprises using
monoclonal antibody 9D2,
[0041] (30) An antibody which specifically binds to a protein
defined in any one of (7), (10) and (11),
[0042] (31) An antibody defined in (30), which is monoclonal
antibody 9D2,
[0043] (32) A method for screening an inhibitor of CLAC-P activity,
which comprises using a protein defined in one of (7), (10) and
(11),
[0044] (33) An inhibitor of CLAC-P activity obtainable by a
screening method defined in (32),
[0045] (34) A method for detection of CLAC-P, which comprises using
an antibody defined in (30),
[0046] (35) A method for treating of, delaying progress of, or
preventing Alzheimer's disease, which comprises using an antibody
defined in (30) or an inhibitor of CLAC-P activity defined in
(33),
[0047] (36) A method defined in (34), in which the antibody is
monoclonal antibody 9D2,
[0048] (37) A method defined in (35), in which the antibody is
monoclonal antibody 9D2,
[0049] (38) A method for purifying CLAC-P, which comprises using
monoclonal antibody 9D2,
[0050] (39) A kit for diagnosing Alzheimer's disease, which
comprises detectably labeled monoclonal antibody 9D2,
[0051] (40) A transgenic animal in which a DNA defined in any one
of (1), (3), (4), (6), (8) and (9) is artificially inserted into,
or deleted from the chromosome.
BRIEF DESCRIPTION OF THE DRAWINGS
[0052] FIGS. 1A and 1B show CLAC-P cDNA nucleotide sequence (SEQ ID
NO:1) and deduced amino acid sequence corresponding thereto (SEQ ID
NO: 2), respectively.
[0053] FIG. 2 shows 9D2 immunostaining of HEK293 cells expressing
CLAC-P (left panel, A) and Western blot of a HEK293 cell membrane
fraction expressing CLAC-P (right panel, B).
[0054] FIG. 3 shows cDNA nucleotide sequence of mouse CLAC-P (SEQ
ID NO: 38).
[0055] FIG. 4 shows deduced amino acid sequence of mouse CLAC-P
(SEQ ID NO: 49).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0056] The first aspect of the present invention is a DNA
comprising a nucleotide sequence of nucleotide 868 to nucleotide
2493 shown in SEQ ID NO: 1, which encodes CLAC.
[0057] The second aspect of the present invention is CLAC having an
amino acid sequence of amino acid 113 to amino acid 654 shown in
SEQ ID NO: 2.
[0058] Novel amyloid molecules CLAC and CLAC-P of the present
invention can be detected by use of specific interaction with
antibodies, as described in Example 2. Partial amino acid
sequences, cDNA sequence, and amino acid sequence thereof can also
be determined. These procedures are briefly described below.
[0059] CLAC and CLAC-P can be detected, for example by following
methods:
[0060] A mouse, for example BALB-C mouse is immunized with senile
plaque amyloid components which are partially purified as an
insoluble fraction from brain of a patient with Alzheimer's disease
by known methods such as sucrose density gradient centrifugation
and urea extraction, and then antibodies, preferably a monoclonal
antibody is obtained. Using the antibody thus obtained, CLAC and
CLAC-P can be detected according to a method (i) or (ii) described
below:
[0061] (i) After cerebral cortex obtained from a patient with
Alzheimer's disease is fixed in 10% formalin, tissue sections are
immunochemically stained, and CLAC or CLAC-P is detected as an
amyloid plaque, or
[0062] (ii) After cerebral cortex obtained from a patient with
Alzheimer's disease is extracted with Tris-buffer and sodium
dodecyl sulfate, the precipitation thus formed is dissolved in 70%
formic acid to obtain an amyloid fraction. The amyloid fraction is
subjected to SDS-electrophoresis and Western blot analysis, and
CLAC or CLAC-P is detected as a polypeptide of 50 to 100
kilodaltons.
[0063] Preferable antibody used is monoclonal antibody 9D2
described in Example 1.
[0064] Partial amino acid sequences of CLAC of the present
invention can be determined, for example by following steps (i) to
(v):
[0065] (i) After cerebral cortex obtained from a patient with
Alzheimer's disease is extracted with Tris-buffer and sodium
dodecyl sulfate (SDS), the precipitation thus formed is dissolved
in 70% formic acid. Amyloid component thus obtained is submitted to
reverse phase high performance liquid chromatography (HPLC), and
fractionated to be separated from A.beta. peptide,
[0066] (ii) 50 kDa and 100 kDa polypeptides are isolated
respectively by gel filtration column,
[0067] (iii) The polypeptide is partially hydrolyzed by a protease
such as lysylendopeptidase, Asp-N or trypsin,
[0068] (iv) Peptide fractions are separated by reverse phase HPLC,
and
[0069] (v) The amino acid sequence of the peptide is determined by
an amino acid sequence analyzer.
[0070] cDNA nucleotide sequence of a precursor of CLAC, i.e. CLAC-P
can be obtained by, for example a method comprising following steps
(i) and (ii):
[0071] (i) Using synthetic oligonucleotide mixture (degenerate
primers) as primers which correspond to nucleotide sequence
encoding a part of a partial amino acid sequence of CLAC obtained
as mentioned above, for example a part of Gly Glu Gln Gly Asp Gln
Gly Pro Arg Met Val Phe Pro Lys Ile Asn H is Gly Phe Leu Ser Ala
Asp Gln Gln Leu Ile Lys (SEQ ID NO: 11), cDNA encoding a part of
CLAC protein is cloned from a complementary DNA (cDNA) library of
human brain by use of polymerase chain reaction (PCR), and
[0072] (ii) Using the nucleotide sequence obtained in step (i) as a
template, "rapid amplification of cDNA ends" method known in the
art is repeated.
[0073] Also, deduced entire amino acid sequence can be obtained by
translating the nucleotide sequence above mentioned into an amino
acid sequence according to a standard method.
[0074] The cDNA sequence of human CLAC-P thus obtained is shown in
SEQ ID NO: 1. This sequence has an ORF (open reading frame)
(nucleotides 532 to 2493) encoding CLAC-P consisting of 654 amino
acids, and the deduced entire amino acid sequence of CLAC-P of the
654 amino acids is shown in SEQ ID NO: 2.
[0075] Alternatively, using cDNA library derived from mouse or rat
brain, and by synthesizing oligonucleotides corresponding to the
nucleotide sequence appropriately selected from human CLAC-P
nucleotide sequence, and using them as primers, PCR method can be
performed to obtain mouse or rat CLAC-P cDNA and amino acid
sequences thereof.
[0076] CLAC of the present invention has following functions: (a)
it accumulates in senile plaque amyloid of Alzheimer's disease, (b)
it promotes aggregation of A.beta..
[0077] Function of CLAC of the present invention to promote A.beta.
aggregation can be estimated by various methods, for example
following methods (1) or (ii):
[0078] (i) One hundred and fifteen .mu.M of synthetic A.beta.
(1-42) peptide [which means that the peptide consists of amino
acids 1 to 42 from the N-terminal] and an appropriate amount of
purified CLAC are mixed, and incubated for 0 to 5 days at room
temperature. The reaction mixture is centrifuged at 15,000.times.g
for 15 min, and the precipitation is suspended in 10 .mu.l of PBS
solution. An appropriate amount of thioflavin T is added, and
analysis is performed in a fluorescence photometer. .lamda.ex is
440 nm, and .lamda.em is 482 nm. Fluorescence obtained is compared
with that obtained by incubation with A.beta. (1-42) only (without
purified CLAC),
[0079] alternatively (ii) it is immunochemically or biochemically
identified that more beta-amyloid plaques are found in brain of a
mouse generated by mating a transgenic mouse over-expressing human
CLAC-P gene with a mouse over-expressing Alzheimer mutant SAPP
gene, than in brain of a transgenic mouse expressing excess
Alzheimer mutant : APP gene only; or it is immunochemically or
biochemically identified that less beta-amyloid plaques are found
in a CLAC-P gene knock-out mouse over-expressing Alzheimer mutant
.beta.APP gene, than in a transgenic mouse over-expressing
Alzheimer mutant .beta.APP gene.
[0080] The third aspect of the present invention is a DNA encoding
variant CLAC protein, in which one or plural amino acids are
inserted into, deleted from, or substituted in CLAC amino acid
sequence, said variant CLAC protein (a) accumulates in senile
amyloid component of Alzheimer's disease, and (b) promotes A.beta.
aggregation.
[0081] Here, insertion, deletion or substitution of one or plural
amino acids can be occurred artificially or naturally. For example,
by known methods in gene-engineering such as site-specific
mutagenesis (M. J. Zoller et al., Methods in Enzymology, 100, 468
(1983)) or PCR method (Molecular Cloning 2nd Ed. Ch. 15, Cold
Spring Harbor Laboratory Press (1989)), these mutations can be
occurred. In addition such insertion, deletion or substitution of
one or plural amino acids can be occurred in vivo. Variants such as
splice variants and allelic variants are included in variant CLAC
protein of the present invention. Moreover partial peptides of CLAC
which have the functions (a) and (b) above mentioned are included
in variant CLAC protein of the present invention. Proteins in which
one or plural amino acids are chemically modified (artificial or
naturally occurring) are also included in variant CLAC protein of
the present invention. Such modifications include, for example
acetylation, amidation, acylation, addition of sugar chain,
phosphorylation, sulfation, addition of lipid, halogenation,
formation of salt, etc. Moreover amino acids other than naturally
occurring twenty L-amino acids (such as D-amino acids, artificial
amino acids) can exist in variant CLAC protein. Homology of a DNA
sequence encoding such a variant CLAC protein to a DNA sequence
encoding the original CLAC (the first aspect of the present
invention) is at least 50%, preferably at least 70%, more
preferably at least 80%, most preferably at least 90%.
[0082] Here, homology means a degree of match between two
nucleotide sequences or amino acid sequences, which is expressed by
percentage. Currently computer software-programs such as
Smith-Waterman algorithm, FASTA or BLAST program, etc. are used to
determine homology.
[0083] The fourth aspect of the present invention is a DNA which
hybridizes to the DNA defined in SEQ ID NO: 3 under a stringent
condition, and encodes a protein having the following properties:
(a) accumulating in senile plaque amyloid component of Alzheimer's
disease, and (b) having a function of promoting aggregation of
A.beta.. Here, "stringent condition" means a condition, for example
in which hybridization occurs only when the nucleotide sequences
have more than 90% homology. As example of stringent condition is:
incubation at 42.degree. C. overnight in a solution containing 50%
formamide, 5.times.SSC (150 mM NaCl, 15 mM sodium citrate), 50 mM
sodium phosphate (pH 7.6), 5.times.Denhart's solution, 10% dextran
sulfate, and 20 ug/ml of danatured and sheered salmon sperm DNA,
then washing in 0.1.times.SSC at 65.degree. C. Hybridization and
washing can be performed by known methods described in for example,
Molecular Cloning 2nd Ed. Ch. 11, Cold Spring Harbor Laboratory
Press (1989) etc.
[0084] The fifth aspect of the present invention is a protein
encoded by either DNA:
[0085] (i) a DNA encoding a variant CLAC protein in which one or
plural amino acids are inserted into, deleted from, or substituted
in CLAC protein shown in SEQ ID NO: 4, said variant CLAC protein
(a) accumulates in senile plaque component of Alzheimer's disease,
and (b) promotes A.beta. aggregation; or
[0086] (ii) a DNA hybridizing to the DNA shown in SEQ ID NO: 3
under a stringent condition, said DNA encodes a protein which (a)
accumulates in senile plaque component of Alzheimer's disease, and
(b) promotes A.beta. aggregation.
[0087] Such proteins include variant CLAC proteins and proteins
having high amino acid sequence homologies to CLAC, which have the
functions (a) and (b) above mentioned. Embodiments of such proteins
include for example variant CLAC proteins above described, partial
peptides of CLAC, and rat or mouse CLAC, etc.
[0088] In this specification, CLAC of the second aspect and variant
CLAC of the fifth aspect can be collectively referred to
"CLAC".
[0089] The sixth aspect of the present invention is CLAC-P DNA
comprises a nucleotide sequence of nucleotide 532 to nucleotide
2493 shown in SEQ ID NO: 1.
[0090] The seventh aspect of the present invention is CLAC-P
comprises an amino acid sequence shown in SEQ ID NO: 2.
[0091] CLAC-P of the present invention functions as an A.beta.
receptor on cell surface.
[0092] Function of CLAC-P of the present invention as an
beta-amyloid receptor can be estimated by various methods, for
example following method:
[0093] HEK293 cells permanently expressing CLAC-P and control cells
are cultivated to confluent state, and 10 .mu.M A.beta. (1-42)
preincubated in a tube for 60 min is added, and incubated for 60
min. Cells collected are solubilized with SDS sample buffer by
sonication, and separated by SDS-polyacrylamide gel
electrophoresis, and Western blotting is performed using
anti-A.beta. antibody, then an amount of A.beta. bound to cells can
be determined.
[0094] Cytotoxicity of A.beta. bound to cells via CLAC-P can be
estimated by following method: for example, PC 12 cells having been
induced to differentiate to nerve cells are made to transiently
express CLAC-P by lipofection method, and A.beta. (1-42)
preincubated for 1 hr is added, and incubated for 1 hr. Thereafter
cells are fixed by 10% formalin, and nuclei showing apoptosis are
stained by TUNEL staining, and then ratio of positive cells is
compared with that of PC12 cells which do not express CLAC-P.
Alternatively,
3-[4,5-dimethylthiazole-2-yl]-2,5-diphenoltetrazolium bromide (MTT)
reagent is added to each well, and amount of MTT reagent
incorporated into living cells may be measured by a
spectrophotometer and compared.
[0095] The eighth aspect of the present invention is a DNA encoding
variant CLAC-P protein in which one or plural amino acids of CLAC-P
are inserted, deleted or substituted, said variant CLAC-P protein
functions as an A.beta. receptor on cell surface.
[0096] Here, insertion, deletion or substitution of one or plural
amino acids can be occurred artificially or naturally. For example,
by known methods in gene-engineering such as site-specific
mutagenesis (M. J. Zoller et al., Methods in Enzymology, 100, 468
(1983)) or PCR method (Molecular Cloning 2nd Ed. Ch. 15, Cold
Spring Harbor Laboratory Press (1989)), these mutations can be
occurred. In addition such insertion, deletion or substitution of
one or plural amino acids can be occurred in vivo. Variants such as
splice variants and allelic variants are included in variant CLAC-P
protein of the present invention. Moreover partial peptides of
CLAC-P which functions as an A.beta. receptor on cell surface are
included in variant CLAC-P protein of the present invention.
Proteins in which one or plural amino acids are chemically modified
(artificial or naturally occurring) are also included in variant
CLAC-P protein of the present invention. Such modifications
include, for example acetylation, amidation, acylation, addition of
sugar chain, phosphorylation, sulfation, addition of lipid,
halogenation, formation of salt, etc. Moreover amino acids other
than naturally occurring twenty L-amino acids (such as D-amino
acids, artificial amino acids) can exist in variant CLAC-P protein.
Homology of a DNA sequence encoding such a variant CLAC-P protein
to a DNA sequence encoding the original CLAC-P (the sixth aspect of
the present invention) is at least 50%, preferably at least 70%,
more preferably at least 80%, most preferably at least 90%.
[0097] The ninth aspect of the present invention is a DNA
hybridizing to a DNA shown in SEQ ID NO: 1 in a stringent
condition, which encodes a protein that functions an A.beta.
receptor on cell surface.
[0098] The tenth aspect of the present invention is a protein
encoded by either DNA:
[0099] (i) a DNA encoding a variant CLAC-P protein in which one or
plural amino acids of CLAC-P are inserted, deleted or substituted,
said variant CLAC-P protein functions as an A.beta. receptor on
cell surface; or
[0100] (ii) a DNA hybridizing to the DNA shown in SEQ ID NO: 1
under a stringent condition, said DNA encodes a protein which
functions as an A.beta. receptor on cell surface.
[0101] Such proteins include variant CLAC-P proteins and proteins
having high amino acid sequence homologies to CLAC-P, which
functions as an A.beta. receptor on cell surface. Embodiments of
such proteins include for example variant CLAC-P proteins above
described, partial peptides of CLAC-P, and rat or mouse CLAC-P,
etc.
[0102] Further, the eleventh aspect of the present invention is a
splice variant of CLAC-P of the present invention. Examples of
splice variants of CLAC-P of the present invention are a
polypeptide shown in SEQ ID NO: 2, in which one to six amino acids
locating amino acid positions 141-146 are deleted or substituted;
or a polypeptide shown in SEQ ID NO: 2, in which one to nine amino
acids locating amino acid positions 589-597 are deleted or
substituted; or a polypeptide shown in SEQ ID NO: 2, in which both
deletion or substitution above described exist at the same time.
Such a variety seems to be attributed to formation of plural kinds
of messenger RNA by alternative selective splicing.
[0103] In this specification, CLAC-P of the seventh aspect, variant
CLAC-P protein of tenth aspect, and splice variant of CLAC-P of
eleventh aspect can be collectively referred to "CLAC-P".
[0104] The twelfth aspect of the present invention is an expression
vector containing a DNA any one of the first, the third, or the
fourth aspect of the present invention. The thirteenth aspect of
the present invention is a transformant which is transformed by
said expression vector. The fourteenth aspect of the present
invention is a method for producing a recombinant protein, which
comprises culturing said transformant under a condition enabling
said vector to be expressed. The recombinant protein thus produced
is also included in the present invention. Such a recombinant
protein is CLAC of any one of the present invention, or variant
CLAC protein which (a) accumulates in senile plaque amyloid
component of Alzheimer's disease, and (b) promotes A.beta.
aggregation.
[0105] The fifteenth aspect of the present invention is an
expression vector containing a DNA of any one of the sixth, the
eighth, or the ninth aspect of the present invention. The sixteenth
aspect of the present invention is a transformant transformed by
said expression vector. The seventeenth aspect of the present
invention is a method for producing a recombinant protein, which
comprises culturing said transformant under a condition enabling
said vector to be expressed. The recombinant protein thus produced
is also included in the present invention. Such a recombinant
protein is CLAC-P of the present invention, or variant CLAC-P
protein which functions as an A.beta. receptor on cell surface. In
aspects relating these aspects, the present invention relates to a
HEK293 cell transformant (deposited to International Patent
Organism Depositary, National Institute of Advanced Industrial
Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi
1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) under accession
No. FERM BP-7438) in which a vector is inserted that contains a
gene encoding CLAC-P. Thus, the present invention also relates to
the CLAC-P gene contained in the deposited strain above mentioned.
In further aspect, the present invention relates to a method for
producing a recombinant protein, which comprises culturing the
transformed strain deposited under a condition enabling the vector
therein containing CLAC-P gene to be expressed. The recombinant
protein thus produced is also included in the present
invention.
[0106] Recombinant proteins can be produced by known methods in the
art, for example the method described in Molecular Cloning 2nd Ed.,
Cold Spring Harbor Laboratory Press (1989). Representative methods
are described:
[0107] Vectors suitable for integration of DNA above described
include, but are not limited to pBR322 (Gene, 2, 95 (1977)), pBR325
(Gene, 4, 121 (1978)), pUC12 (Gene, 19, 259 (1982)), pUC13 (Gene,
19, 259 (1982)), pUC118, pUC119 (Methods in Enzymology, 153, 3
(1987)) from Escherichia coli, pUB110 (Biochemical and Biophysical
Research Communication, 112, 678 (1983)) from Bacillus. Other
vectors can be used which can replicate and are maintained in the
host.
[0108] A method for integration of the DNA above mentioned
includes, for example the method described in Molecular Cloning p.
239, Cold Spring Harbor Laboratory Press (1982).
[0109] A plasmid thus obtained is introduced into a suitable host
such as Escherichia and Bacillus strains.
[0110] Examples of Escherichia strains are, but not limited to
Escherichia coli K12DH1 (Proc. Natl. Acad. Sci. USA, 60, 160
(1986)), M103(Nucleic Acids Research, 9, 309 (1981)), JA221(Journal
of Molecular Biology, 120, 517 (1978)), HB101(Journal of Molecular
Biology, 41, 459 (1969)), C600(Genetics, 39, 440 (1954)).
[0111] A method for transformation includes, for example calcium
chloride method described, or calcium chloride/rubidium chloride
method described in Molecular Cloning p. 249, Cold Spring Harbor
Laboratory Press (1982).
[0112] Desired clones are selected from tranformants thus obtained,
by known methods in the art such as colony hybridization method
(Gene, 10, 63 (1980)) and DNA sequencing method (Proc. Natl. Acad.
Sci. USA, 78, 560 (1977); Nucleic Acids Research, 9, 309
(1981)).
[0113] As described above, microorganism are obtained which retain
a vector carrying a DNA containing cloned gene of the protein of
the present invention.
[0114] Then, the plasmid is isolated from the microorganism.
[0115] A method for isolation includes, but not limited to alkali
method (H. C. Birmbiom et al., Nucleic Acids Research, 1, 1513
(1979)).
[0116] A plasmid having DNA containing cloned gene of the protein
of the present invention, can be used without treatment, or used
after cleavage by restriction enzyme(s).
[0117] An expression vector can be obtained by ligating the cloned
gene of the protein of the present invention into downstream of a
promoter of a vehicle (vector) suitable for expression. Preferred
hosts being transformed by the expression vector are animal cells,
and preferred vectors include expression plasmids for animal cells
(for example pcDNA I, pdKCR-dhfr, etc). Vectors suitable, for
example, for bacterial cells, fungal cells, insect cells, plant
cells can be used so long as they are suitable for production of
the recombinant proteins of the present invention, and such vectors
are well known in the art.
[0118] Said gene may have ATG as a start codon (and optionally a
nucleotide sequence encoding a suitable signal peptide) at the 5'
terminal, or may have TAA, TGA or ATAG (preferably TGA) as a
termination codon at the 3' terminal. Further, promoter(s) is(are)
connected to the upstream of the gene for expression.
[0119] Any expression promoters compatible with the host can be
used in the present invention.
[0120] When the host is an animal cell, promoters derived from
SV40, promoters of retroviruses (not limited to these) can be used,
preferably SV40 promoter is used.
[0121] Animal cells include, but not limited to monkey COS-7 cell,
Chinese hamster ovary cells (CHO cells), neuroblastoma cells, glia
cells, fibroblasts. Preferred cells are those that express and
secrete much protein of the present invention, and particularly
preferable cell is human embryonic kidney fibroblast 293 cell.
[0122] To transform animal cells, for example, the method described
in Virology, 52, 456 (1973) is performed.
[0123] Thus, a transformant is obtained which has been transformed
by a vector containing DNA encoding the protein of the present
invention.
[0124] When a transformant, the host of which is Escherichia or
Bacillus strain, is used, a liquid medium is suitable, in which
carbon sources, nitrogen sources, minerals and so on necessary for
growth of the transformant are included. Examples of carbon sources
are, but not limited to, glucose, dextrin, soluble starch, and
sucrose; examples of nitrogen sources are, but not limited to,
inorganic or organic materials such as ammonium salts, nitrates,
corn steep liquor, corn starch, peptone, casein, meat extract,
soybean meal, and potato extract; examples of minerals are, but not
limited to, calcium chloride, disodium hydrogenphosphate, and
magnesium chloride. Yeast extract, vitamins, growth-promoting
factors, etc may also be added to the medium. Preferably pH of the
medium is about 6 to about 8.
[0125] Preferable medium for cultivation of Escherichia strains is,
for example M9 medium containing glucose and casamino acid (Journal
of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor
Laboratory, New York (1972)). If necessary, an reagent such as
3beta-indoacrylic acid can be added to the medium to make promoter
effective.
[0126] When a host is Escherichia strain, usually cultivation is
carried out at about 15 to about 43.degree. C., for about 3 to
about 24 hours. If necessary, aeration and/or stirring can be
added.
[0127] When a host is Bacillus strain, usually cultivation is
carried out at about 30 to about 40.degree. C., for about 6 to
about 24 hours. If necessary, aeration and/or stirring can be
added.
[0128] When a transformant is cultured, the host of which is an
animal cell, examples of media are, but not limited to, MEM medium
(Science, 122, 501 (1952)), DMEM medium (Virology, 8, 396 (1959)),
RPMI 1640 medium (The Journal of American Medical Association, 199,
519 (1967)), and 199 medium (Proceeding of the Society for the
Biological Medicine, 73 1 (1950)). Five to 20% calf fetal serum can
be added to these madia. Preferable pH of the media is about 6 to
about 8. Usually cultivation is performed at about 30 to about
40.degree. C., and aeration and/or stirring is added, if
necessary.
[0129] Induced expression vector above described in which the gene
of CLAC-P or CLAC of the present invention is integrated, can be
used not only for a large scale production of the vector (by
introducing the vector into a bacterium such as Escherichia coli),
or production of the recombinant protein of the present invention
in various cells, but also for production of transgenic animals as
described below.
[0130] As above described, CLAC-P is a precursor of CLAC (CLAC is
the fragment type thereof), and has an amino acid sequence shown in
SEQ ID NO: 2.
[0131] Processing of CLAC-P to the fragment type CLAC is performed
by cleavage between amino acid 112 (Arg) and amino acid 113 (Glu)
of SEQ ID NO: 2. Therefore, amino acid 113 (Glu) to amino acid 654
(Lys) is the amino acid sequence of CLAC. Usually, the first amino
acid Glu of CLAC is cyclized to be pyroglutamic acid residue.
[0132] CLAC-P is converted to CLAC by actions of processing enzymes
in the body. Such processing enzymes are included in the present
invention. Such processing enzymes can be identified, for example
by any one of the following methods:
[0133] (i) For CLAC secreted or produced by cultured cells
expressing CLAC-P, the culture broth or extracellular matrix
produced around the cells is obtained, and subjected to amino acid
analysis, then the cleaved site is determined by comparing with
CLAC-P, or
[0134] (ii) Known protease inhibitor is added to cells expressing
CLAC-P, and the amount of CLAC protein produced in the culture
broth or in the extracellular matrix is analyzed, using the
decrease in the amount of CLAC protein as an indicator, or
[0135] (iii) Mutation is introduced in the nucleotide sequence of
CLAC-P gene to alter amino acid(s) necessary for cleavage by known
protease, and the mutated gene is expressed. Then the amount of
CLAC protein produced in culture broth or in the extracellular
matrix is analyzed, using the decrease of CLAC protein as an
indicator, or
[0136] (iv) cDNA encoding known protease is further introduced into
cultured cells expressing CLAC-P, and the amount of CLAC protein
produced in the culture broth or the extracellular matrix is
analyzed, using the increase of CLAC protein as an indicator,
or
[0137] (v) cDNA encoding CLAC-P is expressed in cultured cells
lacking known protease, and cultured. Then the amount of CLAC
protein produced in culture broth or in the extracellular matrix is
analyzed, using the decrease of CLAC protein as an indicator.
[0138] Processing enzymes identified by the methods above mentioned
include, but not limited to furin convertase enzyme.
[0139] Inhibitors of the proteases include, but not limited to
decanoyl-RVKR-chloromethylketone which is a competitive inhibitor
of furin convertase and analogous compounds thereof. Cultured cells
expressing CLAC-P is useful in an effective and sensitive screening
of substances that inhibit production or secretion of CLAC because
the cultured cells expressing CLAC-P produce and secrete much CLAC.
Screening of such substances can be performed, for example by
culturing the transformed cells of the present invention in a
medium containing a test substance, and detecting or quantifying
the inhibition of CLAC production or secretion. In said screening
method, changes in CLAC production or secretion from the cells by
the test substance can be detected and quantified, by appropriate
methods such as Western blotting method using an antibody specific
to CLAC.
[0140] Specifically, for example, the transformed cells of the
present invention are plated into multi-well plates, and the cells
are cultured in a DMEM medium containing serum to be confluent.
After the cultured cells are washed in a serum-free medium (DMEM
containing 0.5% bovine serum albumin), a test substance is added to
the same medium, and cells are cultured for a certain period (for
example 24 hours). The amount of CLAC contained in the culture
supernatant or in the extracellular matrix attached on the
multi-well plate is quantified by Western blotting method.
Inhibitory effect of the test substance on CLAC production and/or
secretion is estimated by the amount of CLAC compared with that of
the group without the test substance, or by the concentration of
the test substance to induce decrease of CLAC production and/or
secretion.
[0141] Because the transformed cells of the present invention can
be subcultured, and can produce or secrete much CLAC-P and/or CLAC,
they can be used in screening with high efficacy and high
reproducibility. Therefore the transformed cells can be
advantageously used to screen substances that inhibit CLAC
production or secretion. Moreover a great amount of stable cloned
cells can be always obtained, which makes screening more stable and
effective. Substances identified by such screenings that inhibit
CLAC production and secretion are included in the present
invention.
[0142] A large amount of CLAC can be expressed in cultured cells
and purified, for example by, but not limited to following methods
(i), (ii), or (iii):
[0143] (i) HEK293 cells (ATCC CRL-1573) stably expressing CLAC-P
are cultured in DMEM medium containing 10% FBS for 3 days, then
when the cells reach to semi-confluency, the cells are cultured in
DMEM not containing FBS for 48 hours, then the culture liquid is
recovered. The culture liquid is dialyzed against 50 mM Tris-HCl
(pH 8.6) at 4.degree. C. overnight, thereafter centrifuged at
250,000.times.g for 30 minutes. The precipitate is dissolved in 0.1
M acetic acid, and applied to a DEAE column. Stepwise elution is
performed with 0 M to 1 M NaCl (0.1 M increment) All fractions are
dialyzed against 0.1 M acetic acid, and identification is performed
for example by immunoblotting using a specific antibody 9D2, then
positive fraction is used as purified CLAC fraction (for general
procedures, see Fichard et al., J. Biol. Chem., 272, 30083
(1997)).
[0144] (ii) HEK293 cells stably expressing CLAC-P are cultured in
DMEM medium containing 10% FBS for 3 days, and when the cells reach
to semi-confluency, the cells are cultured in DMEM not containing
FBS for 48 hours, then the culture liquid is recovered. The culture
liquid is dialyzed against 50 mM Tris-HCl (pH 8.6) at 4.degree. C.
overnight, thereafter centrifuged at 250,000.times.g for 30
minutes. The precipitate is dissolved in 0.15 M acetic acid, and
further dialyzed against 20 mM Na.sub.2HPO.sub.4-NaH.sub.2PO.sub.4
(pH7.2) containing 2 M urea (PB/U solution) overnight, thereafter
centrifuged at 250,000.times.g for 30 minutes, and applied to a
heparin column. Stepwise elution is performed with 0 M to 1 M NaCl
(0.1 M increment). All fractions are dialyzed against PB/U, and
identification is performed for example by immunoblotting using a
specific antibody 9D2, then positive fraction is used as purified
CLAC fraction (for general procedures, see Mizuno et al., J. Biol.
Chem., 120, 934 (1996)).
[0145] Or, (iii) CLAC specific antibody (for example 9D2)(1 mg/ml)
is previously bound to NHS activated carrier such as Affigel 10
(Bio-Rad) to obtain an antibody column. HEK293 cells permanently
expressing CLAC-P are cultured in DMEM medium containing 10% FBS
for 3 days, and when the cells reach to semi-confluency, the cells
are cultured in DMEM not containing FBS for 48 hours, then the
culture liquid is recovered. Proteins in the medium are
precipitated with 50% saturated ammonium sulfate. The precipitated
proteins are dissolved in IP buffer (TSI solution [50 mM Tris
(Gibco BRL), 150 mM NaCl (Kanto Kagaku), 0.5 mM DIFP (Wako
Junyaku), 0.5 mM PMSF (Boehringer Mannheim), 1 mM EGTA (Wako
Junyaku), 1 .mu.g/ml antipain (Sigma), 1 .mu.g/ml leupeptin (Wako
Junyaku), 1 .mu.g/ml pepstatin (Sigma), 1 .mu.g/ml TLCK (Sigma)]
containing 0.5% SDS and 0.5% NP-40), filtered by 0.45 .mu.m filter,
and applied to the antibody column above described. Elution is
performed with 0.2 M glycine-HCl (pH 2.6) containing 0.1% Triton
X-100. Eluted fraction is used as purified CLAC (for general
procedures, see Hirako et al., J. Biol. Chem., 273, 9711
(1998)).
[0146] Therefore, further aspect of the present invention is a
method for purification of CLAC using monoclonal antibody 9D2.
[0147] Hybridoma producing monoclonal antibody 9D2 has been
deposited to International Patent Organism Depositary, National
Institute of Advanced Industrial Science and Technology (AIST
Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken,
305-8566, Japan) under accession No. FERM BP-7437.
[0148] Further aspect of the present invention is an antibody which
binds specifically to CLAC-P or CLAC of the present invention.
[0149] Specific antibody to CLAC-P or CLAC can be obtained, for
example by following methods:
[0150] On the basis of amino acid sequences of CLAC and CLAC-P,
peptides such as following peptides are synthesized:
TABLE-US-00001 NC1: (SEQ ID NO: 3) Glu Pro Arg Ser Glu Asp Pro Thr
Pro Ala Glu Gln His Cys (amino acids 14 to 27 of SEQ ID NO: 2)
NC2-1: (SEQ ID NO: 4) Gly Cys Asn His Gly Phe Leu Ser Ala Asp Gln
Gln Leu Ile Lys (amino acids 171 to 183 of SEQ ID NO: 2, Gly and
Cys are added before amino acid 171) NC2-2: (SEQ ID NO: 5) Cys Lys
Gly Glu Gln Gly Asp Gln Gly Pro Arg Met Val Phe Xaa Lys (amino
acids 155 to 169 of SEQ ID NO: 2, Cys is added before amino acid
155) (Xaa represents hydroxyproline) NC3: (SEQ ID NO: 6) Asp Tyr
Asn Gly Asn Leu His Glu Ala Leu Gln Arg Ile Thr Cys (amino acids
430 to 443 of SEQ ID NO: 2, Cys is added after amino acid 443) NC4:
(SEQ ID NO: 7) Leu Gly Pro Asp Gly Leu Pro Met Pro Gly Cys Trp Gln
Lys (amino acids 641 to 654 of SEQ ID NO: 2)
[0151] Then, these peptides bound to KLH (keyhole Limpet
Hemocyanin) are used as antigen to immunize rabbits. Antisera are
obtained by estimating the reactivity with antigen peptides of sera
obtained using ELISA method. Antisera are bound to Affigel to which
antigen peptide is bound, and only specific antigen may be
affinity-purified.
[0152] The splice variant of the eleventh aspect of the present
invention can be also used as above described.
[0153] Antibodies specifically binding to CLAC-P or CLAC of the
present invention may be polyclonal or monoclonal, preferably
monoclonal antibodies. Particularly preferred antibody is 9D2
monoclonal antibody above described.
[0154] Some of such antibodies specifically bind to CLAC or CLAC-P.
Some of such antibodies inhibit actions or functions of CLAC or
CLAC-P. Therefore, further aspect of the present invention is a
method for detecting CLAC or CLAC-P using such antibodies. This
detection method may be applied to diagnosis of Alzheimer's
disease. These antibodies can be labeled with known labels in the
art such as radioactive labels (for example .sup.99Tc), fluorescent
labels or enzymatic labels. These labeled antibodies may be
injected into living animals and scanned the image. Alternatively
bindings of these antibodies to CLAC or CLAC-P protein are detected
and quantified in biopsy or autopsy samples.
[0155] Thus, further aspect of the present invention is a diagnosis
kit for Alzheimer's disease comprising a specific antibody to CLAC
or CLAC-P that is detectably labeled. The kit components may be
directly injected into a living human being and scanned the image.
The kit components may also be reacted with a biopsy or autopsy
sample. Preferred antibody is monoclonal antibody 9D2. Labels
include, but not limited to, radioactive labels (for example
.sup.99Tc), fluorescent labels or enzymatic labels, which can be
selected according to method for use, purpose of use, application
site, etc. Such labels are well known to a skilled person in the
art. The diagnostic kit of the present invention may be composed of
separated vessel containing each component, or composed of several
vessels in which several components are contained. In general, an
appropriate instruction is appended to the kit.
[0156] Still further aspect of the present invention is a method
for screening a inhibitor of CLAC or CLAC-P activity which inhibits
actions and/or functions of CLAC or CLAC-P. Because such an
inhibitor subsequently have effects such as inhibition of A.beta.
accumulation, it can be used as a therapeutic agent of Alzheimer's
disease.
[0157] Such an inhibitor can be screened using for example the
following method (i), (ii) or (iii):
[0158] (i) For a substance which influences binding of CLAC to
beta-amyloid or promotion of amyloid aggregation, a test substance
is added to synthetic A.beta. (1-42) peptide and an appropriate
amount of CLAC, mixed together, and the mixture is incubated for 0
to 5 days at room temperature, then inhibition of formation of
amyloid fibers that emit fluorescence with thioflavin T is
estimated. Alternatively, a test substance is administered orally,
intravenously, or intraventrically to a mouse generated by mating a
transgenic mouse over-expressing human CLAC-P gene with a
transgenic mouse over-expressing Alzheimer mutant : APP gene, or to
a transgenic mouse over-expressing Alzheimer mutant APP gene. Then
decrease of beta-amyloid plaques in brain is immunohistochemically
or biochemically estimated, by comparing with that in brain of a
mouse that has not been given the test substance.
[0159] (ii) For a substance which inhibits binding to beta-amyloid
of cells via CLAC-P, HEK293 cells stably expressing CLAC-P and
control cells are cultured, and 10 .mu.M of A.beta. (1-42) and a
test substance that have been preincubated in a test tube for 60
min are added. Then, the mixture is incubated further 60 min, and
the amount of A.beta. bound to the recovered cells can be
estimated.
[0160] (iii) For a substance that inhibits cytotoxicity of A.beta.
bound to cells via CLAC-P, for example, PC12 cells having been
differentiated to be neurons by NGF are made to transiently express
CLAC-P by lipofection method. Then, A.beta. (1-42) and a test
substance preincubated for 1 hour are added, thereafter the cells
are TUNEL stained to estimate inhibition of apoptosis, or increase
of living cells is estimated by MTT reagent.
[0161] Therefore, further aspect of the present invention is a
method for screening such an inhibitor, comprising using CLAC or
CLAC-P.
[0162] Such inhibitors include, but not limited to antagonists to
CLAC or CLAC-P, polypeptides having similar structures to CLAC or
CLAC-P, or other low molecular compounds.
[0163] Some antibodies that bind specifically to CLAC or CLAC-P of
the present invention, inhibit the actions and/or functions of CLAC
or CLAC-P. Subsequently these antibodies can inhibit accumulation
of A.beta. in brain, and treat, retard or prevent Alzheimer's
disease.
[0164] Thus, another aspect of the present invention is a method to
treat, retard or prevent Alzheimer's disease comprising
administering such an inhibitor or an antibody. Such an inhibitor
or an antibody may be administered solely or with an appropriate
carrier such as purified water or saline. The routes of
administration include intravenous route and intracerebrospinal
cavity route, preferably intravenous route. The dose is normally 1
ug to 100 mg/kg, however the dose can be altered depending on route
of administration, severity of the disease to be treated, condition
of the patient, etc.
[0165] Suitable antibody to the above-mentioned method is
monoclonal antibody 9D2.
[0166] A substance which has therapeutic effect of Alzheimer's
disease by inhibiting production of CLAC or CLAC-P itself, is also
included in the present invention. An example of the method for
screening such a substance is as follows:
[0167] For a substance which has a therapeutic effect via decrease
of CLAC or CLAC-P production, screening can be performed by
culturing the transformed cells of the present invention in a
medium containing a test substance, and detecting or quantifying
production or secretion of CLAC. In said screening method, change
in production or secretion of CLAC from cells by the test substance
can be detected and quantified, using suitable methods such as
Western blotting method using an antibody specific to CLAC.
[0168] Specifically, for example the transformed cells are plated
in a multi-well plate, and cultured in DMEM medium containing sera
to be confluent. After the cells are washed in a serum-free medium
(DMEM containing 0.5% bovine serum albumin), a test substance is
added to the same medium, and cultured for a certain period (for
example 24 hours). The amount of CLAC contained in the culture
supernatant or in the extracellular matrix is quantified by Western
blotting method. And, inhibitory effect of the test substance on
CLAC production and/or secretion is estimated by the amount of CLAC
compared with that in the group not containing the test substance,
or by the concentration of the test substance to induce decrease of
CLAC production and/or secretion. Such a screening method is also
included in the present invention.
[0169] Further a peptide molecule which interacts with CLAC or
CLAC-P and is physiologically useful, can be identified and/or
obtained, for example a method comprising either step of (i), (ii)
or (iii):
[0170] (i) A gene library in which a gene of human CLAC-P is fused
to a gene of DNA binding protein and a gene library in which a gene
of transcription activating protein is fused to cDNAs from human
brain are expressed in yeast cells, and genes showing positive
reactions are obtained by use of two hybrid method.
[0171] (ii) An extract of human brain is passed to a column to
which human CLAC-P or CLAC recombinant protein is bound, and the
bound protein is eluted and submitted to amino acid sequence
analysis.
[0172] (iii) An extract of human brain is passed to a column to
which human CLAC-P is immobilized, and the protein which binds to
the column together with human CLAC-P or CLAC is eluted and
submitted to amino acid sequence analysis.
[0173] Such a peptide molecule is also useful in treatment,
retardation or prevention of Alzheimer's disease. Therefore, such a
peptide molecule, and a method for identifying and/or obtaining it
are also included in the present invention.
[0174] A protein that influences secretion and/or production of
CLAC-P and/or CLAC is also useful in a method for treatment,
retardation or prevention of the present invention. Such a protein
can be identified, for example by making cultured cells expressing
CLAC-P to express human cDNA library, selecting a clone expressing
single cDNA by limiting dilution, and estimating change in the
amount of secreted CLAC from the cell clone, then identifying the
gene introduced. Therefore, such a protein, and a method for
identifying it are also included in the present invention.
[0175] Further aspect of the present invention is a transgenic
animal in which either CLAC DNA or CLAC-P DNA is artificially
introduced into the chromosome, or either DNA is deleted from the
chromosome. A transgenic animal is an animal in which a foreign
gene is introduced by recombinant DNA method. Transgenic animal has
a character that is not obtained by usual breeding. A method for
producing a transgenic animal is well known to a skilled person in
the art. Generally, transgenic animal can be produced by a process
comprising following steps: cloning a gene containing a DNA to be
introduced, ligating the gene to a promoter which expresses in
desired organ and at desired time, introducing the construct into a
fertilized egg, and transplanting the fertilized egg into a
pseudopregnant female animal. By suitably selecting or mutating the
expression regulating sequence, a transgenic animal can be obtained
in which expression of CLAC or CLAC-P of the present invention is
artificially regulated. Knockout animal is also included in
transgenic animal. Such transgenic animals are useful in regulation
of functions or expression of CLAC or CLAC-P of the present
invention, investigation of development of diseases in which CLAC
or CLAC-P involves, screening and development of medicines, etc.
Preferably such transgenic animals are those other than a human
being.
[0176] CLAC-P and CLAC from other animals than a human being can be
cloned. For example, using cDNA library from desired animal, by
amplifying a gene in a similar method to above mentioned, genes of
CLAC-P and CLAC of desired animal can be cloned, and amino acid
sequences thereof can be deduced (for cloning of mouse CLAC-P gene,
see Example 7 of the specification).
EXAMPLES
[0177] The present invention is described by reference of the
Examples below. The Examples should not be construed to limit the
present invention.
Example 1
Preparation of Monoclonal Antibody 9D2
(1) Partial Purification of Senile Plaque Amyloid
[0178] Gray matter was cut out of Alzheimer's brain cortex,
homogenized with a potter homogenizer (Matsushita Electric
Industrial) in TSI solution containing 1 M sucrose (Kanto
Chemicals) [50 mM Tris (Gibco BRL), 150 mM NaCl (Kanto Chemicals),
0.5 mM DIFP (Wako Pure Chemical Industries, Ltd.), 0.5 mM PMSF
(Boehringer Mannheim), 1 mM EGTA (Wako Pure Chemical Industries,
Ltd.), 1 .mu.g/ml antipain (Sigma), 1 M g/ml leupeptin (Wako Pure
Chemical Industries, Ltd.), 1 .mu.g/ml pepstatin (Sigma), 1
.mu.g/ml TLCK (Sigma)], and centrifuged at 260,000.times.g in a
centrifuge (Hitachi Koki) at 4.degree. C. for 30 min.
[0179] The Pellet obtained was suspended in TSI solution
supplemented with 1M sucrose, and fractionated by discontinuous
sucrose density gradient centrifugation (Am. J. Pathol., 148 1517
(1996)) to collect 1.5M sucrose/2.2M sucrose interface.
[0180] The interface collected was treated with DNase I (Wako
Junyaku) at 37.degree. C. for 3 hours, and suspended into TSI
solution containing 1% Triton-X 100 and 5M urea (Nacalai Tesque),
and capillaries were removed (J. Neurochem., 58 1953 (1992)), and
centrifuged (100,000.times.g) in a centrifuge at 4.degree. C. for
30 min.
[0181] Pellets obtained were used as an amyloid fraction.
(2) Preparation of Antibodies
[0182] The senile plaque amyloid fraction was suspended into a 50
mM Tris solution containing 1% SDS, emulsified with a Freund's
complete adjuvant (Sigma), and inoculated to mouse's foodpad
(BALB-C, 7 weeks, male) [J. Exp. Med., 169 1693 (1989)].
[0183] After 25 days from immunization, lymph nodes of posterior
limbs were removed, and lymphocytes were taken out in RPMI medium.
The lymphocytes were fused to myeloma cells (PAI strain) from mouse
myeloma, and hybridomas were prepared. The hybridomas were
suspended in HAT medium, and dispersed into 96-well plates
(Greiner) and cultured for 10 days.
(3) Screening of Monoclonal Antibodies
[0184] Hybridoma supernatants were collected from wells, and
antibodies that stain amyloid positively were selected on smears of
senile plaque amyloid fraction (Am. J. Pathol., 148 1517
(1996)).
[0185] From 288 hybridoma clones, most positive monoclonal antibody
9D2 was selected. Isotype of the monoclonal antibody was identified
as IgG1 by use of Mouse antibody isotype kit (Amersham). A
hybridoma that produce the highest amount of 9D2 antibody was
designated as hybridoma 9D2, and deposited to International Patent
Organism Depositary, National Institute of Advanced Industrial
Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi
1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) and assigned an
accession No. FERM BP-7437 on Jan. 30, 2001.
[0186] Surprisingly it was found that such antibodies bound
strongly and specifically to unknown proteins (referred as CLAC-P
and CLAC in this specification) from Alzheimer's brain. In
particular, monoclonal antibody 9D2 binds very strongly and
specifically to CLAC-P and CLAC. Moreover monoclonal antibody 9D2
is characterized in that it strongly reacts with a peptide fragment
Xaa Ala Pro Ser Glu Cys (SEQ ID NO: 29) in which amino acid 113 Glu
of CLAC-P is changed to pyroglutamic acid.
[0187] Cloning, sequencing, etc of these genes encoding these
unknown proteins (i.e. CLAC-P and CLAC) are described in Example
2.
Example 2
Cloning of Human CLAC-P Gene
[0188] Twenty grams of Gray matter was cut out of Alzheimer's
cerebral cortex, homogenized with a potter homogenizer in TSI
solution, and centrifuged at 260,000.times.g in a centrifuge at
4.degree. C. for 20 min. Pellets obtained was suspended in TSI
solution supplemented with 1M sucrose, and centrifuged at
260,000.times.g in a centrifuge at 4.degree. C. for 20 min. Pellets
obtained were suspended into TSI solution containing 0.32M sucrose,
and capillaries were removed, and centrifuged at 260,000.times.g in
a centrifuge at 4.degree. C. for 20 min. Pellets obtained were
homogenized in TSI solution containing 2% SDS (Nacalai Tesque)
using a homogenizer, and centrifuged at 260,000.times.g in a
centrifuge at 4.degree. C. for 20 min. Pellets obtained were broken
in 70% formic acid (Wako Pure Chemical Industries, Ltd.) by a
sonicator (Branson), and centrifuged at 260,000.times.g in a
centrifuge at 4.degree. C. for 20 min. The supernatant was
freeze-dried in a freeze-drier (Tomy), thereafter suspended in an
aqueous solution of 6M guanidine hydrochloride (Nacalai Tesque),
and centrifuged at 260,000.times.g in a centrifuge at 4.degree. C.
for 20 min. 70% formic acid (1/100 volume of the supernatant) was
added, and separated by RP-HPLC (Hewlett-Packard) using Aquapore
RP300 column (2.1.times.30 mm, Applied Biosystems) [J. Biol. Chem.,
267 17047 (1992)].
[0189] A fraction positive for monoclonal antibody 9D2 was selected
by immunoblotting method using SDS-PAGE (Proc. Natl. Acad. Sci.
USA, 94 2025 (1997)), and it was found that the fraction was eluted
with ca. 30% acetonitrile (Wako Pure Chemical Industries, Ltd.).
After the fraction positive for 9D2 was freeze-dried, the fraction
was suspended in 6 M guanidine hydrochloride aqueous solution,
reduced by reductive carboxy-methylation method (J. Biol. Chem.,
238 622 (1963)), and separated by gel-filtration HPLC using TSKgel
SuperSW3000 column (4.6.times.600 mm, Tosoh). A fraction of ca. 35
kDa to which 9D2 antibody strongly reacted in immunoblotting method
was digested with a lysyl endopeptidase API (achromobacter lyticus
protease I), or Asp-N (Boehringer Mannheim)[J. Biol. Chem., 267
17047 (1992)]. Digests were separated by RP-HPLC using Superspher
Select B column (2.1.times.125 mm, Merck) to obtain a peptide
map.
[0190] A fraction obtained by peptide map was analyzed by a TOF
(time of flight) type mass spectrometer (Bruker-Franzen Analytik)
and an amino acid sequencer (Applied Biosystems) [J. Biol. Chem.,
274 7368 (1999)], and partial amino acid sequences were selected
that had identical molecular weights to those obtained by the mass
spectrometer.
[0191] Sequences obtained are as follows (upper: amino terminal;
bottom: carboxy terminal):
[0192] By digestion enzyme API
TABLE-US-00002 (SEQ ID NO: 8) Ile Asn His Gly Phe Leu Ser Ala Asp
Gln Gln Leu Ile Lys, and (SEQ ID NO: 9) Gly Glu Gln Gly Asp Gln Gly
Hyp Arg Met Val Phe Pro Lys
were obtained (Hyp represents hydroxyproline).
[0193] By digestion enzyme Asp-N
TABLE-US-00003 (SEQ ID NO: 10) Asp Gln Gly Pro Arg Met Val Phe Pro
Lys Ile Asn His Gly Phe Leu Ser Ala
was obtained.
[0194] As a result, following amino acid sequence of 28 amino acids
was obtained as a partial amino acid sequence of 9D2 antigen:
TABLE-US-00004 (SEQ ID NO: 11) Gly Glu Gln Gly Asp Gln Gly Pro Arg
Met Val Phe Pro Lys Ile Asn His Gly Phe Leu Ser Ala Asp Gln Gln Leu
Ile Lys
[0195] On the basis of this sequence, cDNA of 9D2 antigen portion
was cloned by PCR (polymerase chain reaction) method using
degenerated primers. The primers used were designed as follows:
TABLE-US-00005 (SEQ ID NO: 12) 5'-aar ggi gar car ggi gay car ggi
cc-3' (SEQ ID NO: 13) 5'-agc tgc tgr tci gcd gav agr aab cc-3' (SEQ
ID NO: 14) 5'-agc tgc tgr tci gcr ctv agr aab cc-3'
wherein i represents inosine, r represents a or g; y represents c
or t; d represents a, g or t; and v represents a, g or c.
[0196] Using Human brain Marathon-Ready cDNA Library (CLONTECH) as
a template, a 80 bp cDNA fragment was amplified by LA Taq (TaKaRa)
in a PCR apparatus (TaKaRa)--40 cycles of: heat denaturation at
95.degree. C. for 30 sec, annealing at 58.degree. C. for 30 sec,
and DNA synthesis at 72.degree. C. for 1 min. This fragment was
sub-cloned into pBluescript II KS+ (Stratagene), and sequenced by
an automatic sequencer (Li-COR) using Thermo sequencing kit
(Amersham).
[0197] By repeating RACE method using PCR based on the sequence of
the fragment, cloning of CLAC-P DNA was performed that included ORF
(open reading frame) of CLAC-P. Specific primers used are as
follows:
TABLE-US-00006 (SEQ ID NO: 15) 5'-tag ctg ctg gtc ggc gct gag gaa
gcc a-3' (SEQ ID NO: 16) 5'-aag ggg gaa cag ggg gac cag ggg ccg
a-3' (SEQ ID NO: 17) 5'-tcg gaa aca cca tcc tcg gcc cct ggt c-3'
(SEQ ID NO: 18) 5'-cat ggc ttc ctc agc gcc gac cag cag c-3' (SEQ ID
NO: 19) 5'-cgc cgc ctg att aag ggt gac caa gga c-3 (SEQ ID NO: 20)
5'-aag agg gcc acc tgg gga cac agg gaa a-3' (SEQ ID NO: 21) 5'-acc
ctt ggg gcc gtt ctc tcc agc gtc t-3' (SEQ ID NO: 22) 5'-cac ctt gtt
ctc cag gtt ctc cct tag g-3' (SEQ ID NO: 23) 5'-gaa tac cag gac cta
agg gag aac ctg g-3' (SEQ ID NO: 24) 5'-ggc ccc aag ggt gac aca ggc
gaa aag g-3' (SEQ ID NO: 25) 5'-ccc tcc ttt ccc tgc gtg ctt ctt cag
c-3' (SEQ ID NO: 26) 5'-tct cgg ctt cgc ttc cca ccc tct aca c-3'
(SEQ ID NO: 27) 5'-gga gat tct gga atg ccg ggt cca cag g-3' (SEQ ID
NO: 28) 5'-ctt cta tca tag gcc cac cag gcc cac c-3'
[0198] The fragment was amplified by LA Taq (TaKaRa) in PCR
apparatus (TaKaRa) using Human brain Marathon-Ready cDNA Library
(CLONTECH) as a template--35 cycles of: heat denaturation at
95.degree. C. for 30 sec, annealing at 58.degree. C. for 1 min, and
DNA synthesis at 72.degree. C. for 5 min, thereafter nested primer
added--30 cycles of: heat denaturation at 95.degree. C. for 30 sec,
annealing at 60.degree. C. for 1 min, and DNA synthesis at
72.degree. C. for 5 min. The fragment obtained was sub-cloned into
pBluescript II KS+, and sequenced by an automatic sequencer using
Thermo sequencing kit.
[0199] Thus, cDNA of novel protein CLAC-P was obtained (SEQ ID NO:
1). The amino acid sequence of the ORF (SEQ ID NO: 2) was deduced
from the nucleotide sequence. These DNA and amino acid sequences
are shown in FIG. 1.
[0200] cDNA of CLAC-P contains an ORF encoding 654 amino acids in
length (FIG. 1, SEQ ID NO: 1, and SEQ ID NO: 2). CLAC-P is a novel
protein that is type II single pass transmembrane protein. Its
amino terminal is located on the cytoplasmic side, and its carboxy
terminal is on the extracellular side. The amino acid sequence has
three repeats of collagen-like Gly-Xaa.sub.1-Xaa.sub.2 (G
represents glycine; Xaa.sub.1 and Xaa.sub.2 represent any amino
acids) in the extracellular region. mRNA expression was
investigated in various human tissues using RT-PCR method, and
specific expression was found in brain and testis. A peptide
antibody prepared on the basis of the deduced amino acid sequence
stained senile plaques in Alzheimer's brain, and it was found that
the protein fragment derived from the cDNA obtained accumulated in
senile plaque amyloid.
Example 3
Assay of Amyloid Beta Peptide Receptor Function of CLAC-P Using
Human Transformed Cells that Permanently Express Human CLAC-P
[0201] A plasmid DNA in which CLAC-P gene was integrated was
prepared as described below: CLAC-P gene was altered to be cleaved
at position -40 of 5' UTR region of CLAC-P by HindIII, and at
position +100 from the first stop codon of the 3' UTR region. The
altered CLAC-P gene was integrated into HindIII-BamHI region of
multicloning site of pcDNA3.1/Hygro(+) (invitrogen) having CMV
promoter.
[0202] HEK293 cells were plated into 6-well plates (Nunc) at a
concentration of 3.0-5.0.times.10.sup.5 cells/well, and cultured
for 24 hours. Then, solution A.beta. 1 ug plasmid DNA/100 .mu.l
Opti-MEM(Gibco BRL) and solution B: 10 .mu.l LipofectAMINE (Gibco
BRL)/100 .mu.l Opti-MEM are prepared, mixed together and incubated
for 30 min, then 800 .mu.l of Opti-MEM was added to the mixture to
1 ml (DNA-Lipofectamine complex) (per well). DMEM was removed from
the cells, and the cells was washed with Opti-MEM (1.times.), then
1 ml of DNA-Lipofectamine complex was added to each well and
cultured for 6 hours. Then 1 ml of DMEM containing 20% FBS was
added, and cultured for further 24 hours. After replacement of the
medium to DMEM, cultured for further 24 hours. Thereafter the cells
in each well were re-plated into 10 cm dish, and selection culture
was performed in DMEM containing 133 mg/ml of hygromycin (Wako
Junyaku). After selection culture for 10-14 days, grown cells are
taken as polyclonal cell strains in which desired plasmid was
introduced. Polyclonal cell strains were further cloned by limited
dilution method, and 15 monoclonal cell strains were obtained. The
monoclonal cell strains were analyzed for their expression by
immunoblotting using an antibody specific to CLAC-P protein. Three
strains that showed maximum expression were selected, designated as
9D2-1, 9D2-2, and 9D2-11, and used subsequent experiments. Strain
9D2-1 which was a transformant of HEK293 cell permanently
expressing human CLAC-P was deposit to International Patent
Organism Depositary, National Institute of Advanced Industrial
Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi
1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) and assigned an
accession No. FERM BP-7438 on Jan. 30, 2001.
[0203] Cover glasses pre-coated with poly-L-lysine (Sigma, 10
ug/ml) were arranged on 10 cm dishes, upon which cells were
applied, cultured, gene-introduced, and recovered the cover
glasses. The cover glasses were washed with PBS solution
(2.times.), then fixed with PBS solution containing 4%
paraformaldehyde (TAAB) at room temperature for 30 min. After
further washing with PBS solution (2.times.), permeabilization and
blocking were performed with PBS solution containing 0.5% Triton
X-100, 0.3% BSA (Bovine serum albumin, Sigma) at room temperature
for 30 min. The solution was removed, and an antibody was added
which was diluted (1/1000) with PBS solution containing 0.3% BSA,
and reacted at room temperature for 2 hours. After washing with PBS
(3.times.), FITC-bound-anti-rabbit antibody (Jackson) as a
secondary antibody was added which was diluted with PBS solution
containing 0.3% BSA, then reacted at room temperature for 1 hour
with glare protection. After washing with PBS (3.times.), the
sample was encapsulated with a encapsulating agent and observed
using a fluorescent microscope. (AX-80, Olympus). Distribution of
CLAC-P was observed in cell membrane system, particularly
endoplasmic reticulum, Golgi apparatus and cell surface
membrane.
[0204] After monoclonal HEK293 strain stably expressing CLAC-P
cultured in 10 cm dish was washed in TS solution, the strain was
recovered by cell-scraper in TSI solution. The cells were disrupted
in a polytron homogenizer (Hitachi Koki), then centrifuged at
1,000.times.g, 4.degree. C., for 7 min. The supernatant was
collected, and centrifuged at 2,000.times.g, 4.degree. C., for 30
min. The pellet was used as a mitochondria and lysosome fraction.
The supernatant was further ultra-centrifuged at 100,000.times.g,
4.degree. C., for 60 min. The pellet was recovered as a microsome
fraction and analyzed, and the supernatant was recovered as
cytoplasmic fraction and analyzed. As shown in right panel (B) of
FIG. 2, expression of a full length CLAC-P protein of 80 kDa was
detected specifically in membrane fraction of CLAC-P expressing
cells.
[0205] HEK293 cells permanently expressing human CLAC-P, and
control cells permanently expressing pcDNA3.1 vector only were
cultured in 10 cm dishes, and when reached to confluent, 10 .mu.M
A.beta. (1-42) (Bachem) preincubated at 37.degree. C. for 60 min
was added, and incubated for a certain period. After incubation,
culture supernatant containing A.beta. was removed, and the cells
were washed in PBS (3.times.), then collected by a scraper, and
precipitated in a microcentrifuge (TOMY) at 7,000 rpm for 5 min.
Sample buffer was added to the cell pellet, and solubilized by
sonication, and the protein was quantified using BCA protein assay
kit (Piearce).
[0206] The amounts of the proteins contained each sample were
adjusted to be a certain level, and 2-mercaptoethanol was added
(final concentration was 1%), and heated for 10 min. The proteins
were separated by SDS-PAGE using 15% Tris-Tricine gel, and
transferred to a nitrocellulose membrane (Hybon-ECL, Amersham)
under a condition of 3 hours at 150 mA. Transferred membrane was
heated in PBS for 10 min, then blocked in 1% skim milk (Difco)-PBS
at room temperature for 30 min, and reacted with various antibodies
diluted by similar blocking solution at room temperature for 2
hours, or at 4.degree. C. overnight. The membrane was reacted
solution at room temperature for 1 hour with a secondary antibody
(anti-mouse or anti-rabbit Ig, horseradish peroxidase bound whole
antibody (Amersham)) that were washed in PBS-T (PBS containing 0.1%
Tween 20) for 10 min (3.times.), then diluted with similar
blocking. After washing in PBS-T for 10 min (3.times.), exposed to
Hyperfilm-ECL (Amersham) using ECL kit (Amersham), and A.beta.
binding was detected. Cells expressing human CLAC-P bound 30 ng of
A.beta. (1-42) per mg protein, while cells expressing the vector
only bound 6 ng of A.beta.. As the result of above experiment,
binding of A.beta. increased five times, which indicated that human
CLAC-P expressed on cell surface acts as a receptor for
A.beta..
Example 4
Amino Acid Sequence of CLAC from Amyloid in Human Alzheimer's
Brain, and the Reactivity with 9D2 Antibody
[0207] CLAC purified from human Alzheimer's brain according to the
method of (1) described in Example 2, was subjected to amino acid
analysis, however it was impossible to analyze the protein because
the amino terminal was blocked. A peptide corresponding to amino
acids 113-118 of CLAC-P, Xaa Ala Pro Ser Glu Cys (SEQ ID NO: 29)
was synthesized in which amino acid 113 Glu was substituted with
pyroglutamic acid (Xaa). The peptide was bound to KLH through Cys
residue, then the bound peptide was used as an immunogen to produce
an antibody (hereinafter, said antibody is referred as PyroG). As
inferred from the description of Neuron, 14 457 (1995), antigen
PyroG specifically recognized the structure of the amino terminal
opposite to the KLH binding side of the synthesized peptide.
Namely, PyroG did not react with full length recombinant CLAC-P
protein obtained by expression in cultured cells according to the
method of Example 3 when immunoblotting method was performed using
SDS-PAGE. However, Xaa Ala Pro Ser Glu Cys (SEQ ID NO: 29) peptide
was immobilized to a micro-well plate (according to the method of
EMBO J., 11, 2895 (1992)), and enzyme-linked immunosorbent assay
(ELISA) was performed by indirect peroxidase method using PyroG
antibody as a primary antibody. In the ELISA, positive reaction was
found. Also, CLAC obtained from human Alzheimer's brain as above
described reacted positively with PyroG in immunoblotting method.
Further, positive reaction of 9D2 antibody and CLAC from
Alzheimer's brain in immunoblotting method, and immunohistochemical
staining with Alzheimer's brain tissue specimen were diminished by
preliminary mixing Xaa Ala Pro Ser Glu Cys with (SEQ ID NO:: 29)
9D2 antibody to absorb the antibody activity (according to Neuron,
13, 45 (1994)). These facts indicated that CLAC from Alzheimer's
brain amyloid starts from amino acid 113 of CLAC-P and the amino
acid 113 is pyroglutamic acid and that 9D2 antibody recognizes CLAC
protein underwent such a modification.
Example 5
In Vitro Binding of CLAC to Beta-Amyloid (A.beta.)
[0208] In vitro binding of CLAC to A.beta. was performed according
to a method of Webster et al. (Am. J. Pathol., 150, 1531
(1997)).
[0209] The transformant (strain 9D2-1) permanently expressing human
CLAC-P obtained in Example 3 was selection-cultured in DMEM medium
containing 10% FBS and hygromycin for 4 days, and the culture
supernatant was collected. Fifty .mu.l (0.1 mg/ml) of synthetic
A.beta. (1-42) (Bachem) was immobilized to each well of 96-well
micro-well plates (Greiner), and dried in a desiccator. Thereafter,
blocking was performed with PBS-T containing 1% gelatin (Wako
Junyaku) for 1 hour, and washed with PBS-T for 10 min (3.times.),
and the culture supernatant obtained was applied. Similarly,
culture supernatant of control HEK293 cells used in Example 3 was
applied. After reaction at room temperature for 1 hour, washed with
PBS-T for 10 min (5.times.), and then reacted with anti-CLAC
antibody diluted with similar blocking solution (1/5000) at room
temperature for 1 hour. After washing with PBS-T for 10 min
(5.times.), reacted with a secondary antibody (anti-rabbit Ig,
horseradish peroxidase bound whole antibody (Amersham)) diluted
with similar blocking solution (1/5000) at room temperature for 1
hour. After washing with PBS-T for 10 min (5.times.), colour was
developed with TMB reagent (Kirkegard & Perry
Laboratories).
[0210] As a result of ten trials, the culture supernatant of
transformant permanently expressing CLAC-P that secretes CLAC
developed stronger colour about fifty times than control HEK293
that does not secrete CLAC, which indicates that CLAC significantly
binds to A.beta. (p<0.0001) in vitro.
Example 6
Effects of CLAC on A.beta. Aggregation
[0211] The transformant (strain 9D2-1) permanently expressing human
CLAC-P obtained in Example 3 was selection-cultured in DMEM medium
containing hygromycin and 10% FBS for 3 days, and cultured starting
from semi-confluency for 4 days in DMEM not containing FBS, and
then the culture supernatant was collected. After centrifugation at
2,000.times.g, the supernatant was applied to a DEAE column
(Whatman), and the through-pass fraction was further applied to a
heparin column (Amersham). After washing the column fully with PBS
solution containing 2M urea (Nacalai Tesque) (PB-U solution),
elution was performed with PB-U solution containing 1M NaCl, and
the eluate was dialyzed against PBS solution. The solution thus
obtained was used as crude purified CLAC, and the solution obtained
from control HEK293 cells was used as a control.
[0212] Experiment of A.beta. aggregation was performed according to
the standard method of LeVine (Methods in Enzymology, 309,
274).
[0213] One hundred .mu.l of the crude purified CLAC or the solution
from control HEK293 cells was added to 3.6 .mu.M synthesized
A.beta. (1-42) (Bachem), and after passing through 0.22 .mu.M
filter, reacted at 37.degree. C. for 1 day. Four hundred .mu.l of
glycine-NaOH solution (10 .mu.M, pH=8.5) containing 3 .mu.M
thioflavin T was added to the reaction mixture, and the
fluorescence was measured in a fluorophotometer (Hitachi F-2000)
(excitation at 442 nm; measurement at 496 nm).
[0214] By eighteen trials, it was shown that A.beta. aggregated
with the crude purified CLAC sixty times as much as with the
solution from the control HEK293 cells, and this result was
significant (p<0.0001).
Example 7
Cloning of Mouse CLAC-P cDNA
[0215] Mouse brain Marathon-Ready cDNA Library (CLONTECH) was used
as a template, mouse CLAC-P cDNA was cloned by PCR method.
Following primers were prepared based on human CLAC-P cDNA
sequence:
TABLE-US-00007 (SEQ ID NO: 30) 5'-GGG ATC AAG GAG CCA CTA AGA TCA
TAG primer 1 A-3' (SEQ ID NO: 31) 5'-GGG CCT ATG ATA GAA GGA CCC
TGT GGA primer 2 C-3' (SEQ ID NO: 32) 5'-CTA CAA CGG CAA CCT CCA
CGA AGC CTT-3' primer 3 (SEQ ID NO: 33) 5'-TCT CCC TTT ATC CCC GGA
AGT C-3' Primer 4
[0216] Using primers 1 and 2, a cDNA fragment of about 330 bp was
amplified by PCR apparatus (TaKaRa) using PremixLATaq (TaKaRa)--40
cycles of: heat denaturation at 95.degree. C. for 45 sec, annealing
at 42.degree. C. for 45 sec, DNA synthesis at 72.degree. C. for 3
min. Then, the reaction mixture as a template was added to
PremixLATaq (1:50), and using primers 2 and 3, nested PCR was
performed--35 cycles of: heat denaturation at 95.degree. C. for 45
sec, annealing at 51.degree. C. for 45 sec, DNA synthesis at
72.degree. C. for 3 min. Thus, a fragment of about 300 bp was
obtained. This fragment was purified, and sub-cloned into
pBluescript II KS+(Stratagene) by TA cloning method, and sequenced
using an automatic sequencer (Li-COR) (SEQ ID NO: 50).
[0217] By searching on the basis of human CLAC-P, a sequence of
about 70 bp from adult mouse testis was found in GenBank (AV264752,
SEQ ID NO: 51) that has a high homology to human CLAC-P. Based on
this sequence and the sequences previously obtained, new primers
were synthesized:
TABLE-US-00008 (SEQ ID NO: 34) 5'-CGA ATA TAT GGC TAA AAT AAG AAC
GGT primer 5 C-3' (SEQ ID NO: 35) 5'-CTG GCA AAC CGG TGT CTC CTT
TCT CTC-3' primer 6 (SEQ ID NO: 36) 5'-ACG GTC AGG GAG GCA CCT TTA
GAG TGC primer 7 A-3' (SEQ ID NO: 37) 5'-CTC TCC TTT TAC TCC ATT
GGC ACC CGG primer 8 C-3' (SEQ ID NO: 38) 5'-ACG GTC AGG GAG GAA
GCT TTA GAG TGC primer 9 A-3' (SEQ ID NO: 39) 5'-TCA ACT CCG GGG
ATC CCT GGA GAG CCT primer 10 T-3'
[0218] Firstly, using primers 5 and 6, PCR reaction was
performed--38 cycles of: heat denaturation at 95.degree. C. for 45
sec, annealing at 55.degree. C. for 45 sec, DNA synthesis at
72.degree. C. for 3 min. Using this reaction mixture as a template,
and using primers 7 and 8, PCR was performed in same conditions to
amplify a fragment of about 1200 bp. The fragment was purified, and
using primer 4 synthesized as a dye-primer, the nucleotide sequence
was analysed by an automatic sequencer. Based on this nucleotide
sequence, the following primers were prepared:
TABLE-US-00009 (SEQ ID NO: 40) 5'-GGG ACC ATT TTC TCG AGC ATC TCC
CTT primer 11 T-3' (SEQ ID NO: 41) 5'-AAA ATG GTC CCA AAG GTG ATA
CAG GAG-3' primer 12
[0219] Using the reaction mixture obtained by PCR using primers 5
and 6 as a template, and using primers 9 and 11, PCR reaction was
performed--38 cycles of: heat denaturation at 95.degree. C. for 45
sec, annealing at 56.degree. C. for 45 sec, DNA synthesis at
72.degree. C. for 3 min. A fragment of about 560 bp thus obtained
was digested with XhoI and HindIII. A XhoI-HindIII fragment was
sub-cloned into pBluescript II KS+, and the nucleotide sequence was
identified (SEQ ID NO: 52). Also, using the reaction mixture
obtained by PCR using primers 5 and 6 as a template, and using
primers 10 and 12, PCR reaction was performed--38 cycles of: heat
denaturation at 95.degree. C. for 45 sec, annealing at 56.degree.
C. for 45 sec, DNA synthesis at 72.degree. C. for 3 min. A fragment
of about 550 bp thus obtained was digested with XhoI and HindIII. A
XhoI-HindIII fragment was sub-cloned into pBluescript II KS+ TA
cloning method, and the nucleotide sequence was identified (SEQ ID
NO: 53).
[0220] Next, RACE (rapid amplification of cDNA ends) method was
performed on the basis of these sequences. Following primers were
used:
TABLE-US-00010 (SEQ ID NO: 42) 5'-TGC ACT CTA AAG GTG CCT CCC TGA
CCG primer 13 T-3' (SEQ ID NO: 43) 5'-GAC CGT TCT TAT TTT AGC CAT
ATA TTC primer 14 G-3' (SEQ ID NO: 44) 5'-TGG TAA CCT CCA TGA GGC
CTT ACA GAG primer 15 A-3' (SEQ ID NO: 45) 5'-GAG AGA AAG GAG ACA
CCG GTT TGC CAG-3' primer 16 (SEQ ID NO: 45) 5'-GGC TGG ATG CTC CTT
GCC AAT TGG GA-3' primer 17 (SEQ ID NO: 46) 5'-TGG GAC CTG ATG GGT
TAC CTA TGC CTG-3' primer 18
[0221] Using mouse brain Marathon-Ready cDNA Library (CLONTECH) as
a template, PCR reaction was carried out--cycles of heat
denaturation at 95.degree. C. for 45 sec, annealing at 59.degree.
C. for 45 sec, DNA synthesis at 72.degree. C. for 5 min were
repeated. Nested PCR was applied to the reaction mixture--cycles of
heat denaturation at 95.degree. C. for 45 sec, annealing at
60.degree. C. for 45 sec, DNA synthesis at 72.degree. C. for 5 min
were repeated to amplify a fragment. The fragment was sub-cloned
into pBluescript II KS+ by TA cloning method, and the nucleotide
sequence was identified (SEQ ID NOs: 54, 55 and 56).
[0222] From these DNA fragments, the sequence of mouse CLAC-P cDNA
was determined (FIG. 3 and SEQ ID NO: 48). From this cDNA sequence,
the amino acid sequence of the ORF was deduced (FIG. 4 and SEQ ID
NO: 49). Mouse CLAC-P cDNA encoded 666 amino acids (full length).
Its homology to human CLAC-P cDNA was about 83%, and about 90% at
amino acid level. The molecular structure of mouse CLAC-P was
basically the same as human CLAC-P, and it was type II single pass
transmembrane protein, and had three collagen-like repeat in the
extracellular region. Moreover within the collagen-like sequence, a
sequence that undergoes alternative splicing (FIG. 4, underlined;
SEQ ID NO: 49) was identified.
PROBABILITY OF INDUSTRIAL USE OF THE INVENTION
[0223] Novel collagen-like protein CLAC obtained in the present
invention accumulates in Alzheimer's senile plaque amyloid, and
promotes aggregation of beta-amyloid that is the main component of
Alzheimer's senile plaque amyloid. CLAC-P, a precursor of CLAC, is
distributed on the surface of cell membrane as a transmembrane
protein, and acts as a receptor that binds beta-amyloid to the cell
surface. Thus CLAC-P is involved in the progress of Alzheimer's
disease. CLAC-P can be useful in prevention, retardation and
treatment of Alzheimer's disease.
Sequence CWU 1
1
5612607DNAHomo sapiens 1ccgcgacttc ggcttcgcga gtagcattgg ttccttgggt
ttatttcgtt ttcctctctc 60ttctccacct tagtcgcccc tttcgcgctg cgctgtagcg
tgctctcaca gcctttttgc 120cttgaactga atgcaggtgg gaaacaggtc
ggcgtgccga aagacaccga gtaggtagaa 180ataaggcaaa ctcacagagg
cgcaacaggt ccggtcctcc gtggccaggg cgagccgcgg 240ccccgcgtgg
cgcctcggcc gttgccctcg gaccctgagc ggccactgtt ggggccctcg
300aaagaggtgt cggtcctctg ggagtcggaa gagctgtctg ggtgggtttc
gtcttgcttt 360ttaccccacc gccacccagt ccccggacgg agggtgcttt
tcacttccag ctgggaggag 420agaagaaagc ggggatggtg cacgcctgcg
ggtctggacg ctgagcaagg caggggatta 480tttgaggtgt agagggtggg
aagcgaagcc gagacggccg accccgccac gatgctgctg 540aagaagcacg
cagggaaagg agggggccgg gagcccagat ccgaggaccc gacccctgcc
600gaacagcatt gttcccggac catgcccccg tgtgccgtcc tggcggccct
cctgtcagtg 660gtggccgtgg tgtcttgcct gtacctgggt gtgaaaacca
acgacctcca ggcgaggatc 720gccgctctcg aatccgccaa aggggccccc
tccattcatc tgctgcctga taccctggat 780cacctcaaga ctatggtgca
agagaaagtg gagcgacttc tggctcagaa atcctatgaa 840catatggcta
aaataagaat cgcaagagaa gcaccttcag aatgtaactg cccagcaggc
900cctccaggga aacgaggtaa gagaggccga agaggagaat ctggtcctcc
tggacagcct 960ggtcctcagg gccctcctgg tccaaaaggc gataagggag
aacaaggtga tcagggacct 1020aggatggtgt ttcctaaaat caatcatggg
tttctctctg ctgatcagca gctcattaaa 1080cgccgcctga ttaagggtga
ccaaggacag gcagggcctc caggaccccc tggccctcca 1140ggcccaagag
ggccacctgg ggacacaggg aaagatggcc cccgtggaat gccaggagta
1200cccggtgaac caggaaagcc aggagaacaa ggcttgatgg gtcctctagg
gcctccggga 1260caaaagggtt ctattggagc acctggaatt ccagggatga
atgggcaaaa gggtgagccc 1320gggttgcctg gagcagtagg acagaatgga
ataccaggac ctaagggaga acctggagaa 1380caaggtgaaa agggagacgc
tggagagaac ggccccaagg gtgacacagg cgaaaagggt 1440gaccctggat
catctgctgc aggaattaag ggagaacctg gggaatctgg tcgtccaggg
1500caaaagggtg aaccagggct tcctgggctt cctggacttc cggggataaa
gggagaacca 1560ggtttcattg gtcctcaagg agaaccaggc ttaccaggtt
taccaggaac aaaaggtgaa 1620cggggggaag cagggcctcc tggaagaggt
gagcgagggg aacctggagc ccccggacca 1680aaggggaaac aaggtgaatc
aggaactaga ggcccaaagg ggtcaaaggg ggatcgtgga 1740gaaaaagggg
actctggagc tcagggacca aggggtccac ctggtcaaaa aggggatcaa
1800ggagccacta agatcataga ctacaacggc aacctccacg aagccttaca
gaggattacc 1860accttaactg tcacgggtcc ccctggacct cctggacctc
aaggactaca agggccaaag 1920ggagagcagg gatctccagg aatcccagga
atggatggag agcagggact caaaggctca 1980aagggagaca tgggggaccc
aggtatgaca ggtgaaaaag gaggaattgg acttcctgga 2040ttaccgggag
ccaatggaat gaaaggagaa aaaggagatt ctggaatgcc gggtccacag
2100ggtccttcta tcataggccc accaggccca ccaggtcccc atggcccacc
tggccccatg 2160ggacctcatg gacttcctgg accaaagggt acagatggtc
ctatgggacc ccatggccct 2220gcaggtccca aaggagaaag aggtgaaaaa
ggagctatgg gagagcctgg accaagaggg 2280ccctatgggc tgcctgggaa
agatggagag cctggtcttg atggcttccc tggtccacgg 2340ggtgagaagg
gtgatctagg agaaaaggga gaaaagggat tccgtggcgt taagggggaa
2400aaaggggagc caggccagcc tggcctggat gggctggatg ccccttgcca
attggggcca 2460gatggcttac ccatgcctgg ctgttggcaa aagtgatgaa
tctaaccttt caagcatgaa 2520gttgtgtata taagggtcca tttttaatat
ttatagttga aaactgaatt gcagatttta 2580caagtctgag atatgtttac atagggc
26072654PRTHomo sapiens 2Met Leu Leu Lys Lys His Ala Gly Lys Gly
Gly Gly Arg Glu Pro Arg1 5 10 15Ser Glu Asp Pro Thr Pro Ala Glu Gln
His Cys Ser Arg Thr Met Pro 20 25 30Pro Cys Ala Val Leu Ala Ala Leu
Leu Ser Val Val Ala Val Val Ser 35 40 45Cys Leu Tyr Leu Gly Val Lys
Thr Asn Asp Leu Gln Ala Arg Ile Ala 50 55 60Ala Leu Glu Ser Ala Lys
Gly Ala Pro Ser Ile His Leu Leu Pro Asp65 70 75 80Thr Leu Asp His
Leu Lys Thr Met Val Gln Glu Lys Val Glu Arg Leu 85 90 95Leu Ala Gln
Lys Ser Tyr Glu His Met Ala Lys Ile Arg Ile Ala Arg 100 105 110Glu
Ala Pro Ser Glu Cys Asn Cys Pro Ala Gly Pro Pro Gly Lys Arg 115 120
125Gly Lys Arg Gly Arg Arg Gly Glu Ser Gly Pro Pro Gly Gln Pro Gly
130 135 140Pro Gln Gly Pro Pro Gly Pro Lys Gly Asp Lys Gly Glu Gln
Gly Asp145 150 155 160Gln Gly Pro Arg Met Val Phe Pro Lys Ile Asn
His Gly Phe Leu Ser 165 170 175Ala Asp Gln Gln Leu Ile Lys Arg Arg
Leu Ile Lys Gly Asp Gln Gly 180 185 190Gln Ala Gly Pro Pro Gly Pro
Pro Gly Pro Pro Gly Pro Arg Gly Pro 195 200 205Pro Gly Asp Thr Gly
Lys Asp Gly Pro Arg Gly Met Pro Gly Val Pro 210 215 220Gly Glu Pro
Gly Lys Pro Gly Glu Gln Gly Leu Met Gly Pro Leu Gly225 230 235
240Pro Pro Gly Gln Lys Gly Ser Ile Gly Ala Pro Gly Ile Pro Gly Met
245 250 255Asn Gly Gln Lys Gly Glu Pro Gly Leu Pro Gly Ala Val Gly
Gln Asn 260 265 270Gly Ile Pro Gly Pro Lys Gly Glu Pro Gly Glu Gln
Gly Glu Lys Gly 275 280 285Asp Ala Gly Glu Asn Gly Pro Lys Gly Asp
Thr Gly Glu Lys Gly Asp 290 295 300Pro Gly Ser Ser Ala Ala Gly Ile
Lys Gly Glu Pro Gly Glu Ser Gly305 310 315 320Arg Pro Gly Gln Lys
Gly Glu Pro Gly Leu Pro Gly Leu Pro Gly Leu 325 330 335Pro Gly Ile
Lys Gly Glu Pro Gly Phe Ile Gly Pro Gln Gly Glu Pro 340 345 350Gly
Leu Pro Gly Leu Pro Gly Thr Lys Gly Glu Arg Gly Glu Ala Gly 355 360
365Pro Pro Gly Arg Gly Glu Arg Gly Glu Pro Gly Ala Pro Gly Pro Lys
370 375 380Gly Lys Gln Gly Glu Ser Gly Thr Arg Gly Pro Lys Gly Ser
Lys Gly385 390 395 400Asp Arg Gly Glu Lys Gly Asp Ser Gly Ala Gln
Gly Pro Arg Gly Pro 405 410 415Pro Gly Gln Lys Gly Asp Gln Gly Ala
Thr Lys Ile Ile Asp Tyr Asn 420 425 430Gly Asn Leu His Glu Ala Leu
Gln Arg Ile Thr Thr Leu Thr Val Thr 435 440 445Gly Pro Pro Gly Pro
Pro Gly Pro Gln Gly Leu Gln Gly Pro Lys Gly 450 455 460Glu Gln Gly
Ser Pro Gly Ile Pro Gly Met Asp Gly Glu Gln Gly Leu465 470 475
480Lys Gly Ser Lys Gly Asp Met Gly Asp Pro Gly Met Thr Gly Glu Lys
485 490 495Gly Gly Ile Gly Leu Pro Gly Leu Pro Gly Ala Asn Gly Met
Lys Gly 500 505 510Glu Lys Gly Asp Ser Gly Met Pro Gly Pro Gln Gly
Pro Ser Ile Ile 515 520 525Gly Pro Pro Gly Pro Pro Gly Pro His Gly
Pro Pro Gly Pro Met Gly 530 535 540Pro His Gly Leu Pro Gly Pro Lys
Gly Thr Asp Gly Pro Met Gly Pro545 550 555 560His Gly Pro Ala Gly
Pro Lys Gly Glu Arg Gly Glu Lys Gly Ala Met 565 570 575Gly Glu Pro
Gly Pro Arg Gly Pro Tyr Gly Leu Pro Gly Lys Asp Gly 580 585 590Glu
Pro Gly Leu Asp Gly Phe Pro Gly Pro Arg Gly Glu Lys Gly Asp 595 600
605Leu Gly Glu Lys Gly Glu Lys Gly Phe Arg Gly Val Lys Gly Glu Lys
610 615 620Gly Glu Pro Gly Gln Pro Gly Leu Asp Gly Leu Asp Ala Pro
Cys Gln625 630 635 640Leu Gly Pro Asp Gly Leu Pro Met Pro Gly Cys
Trp Gln Lys 645 650314PRTHomo sapiens 3Glu Pro Arg Ser Glu Asp Pro
Thr Pro Ala Glu Gln His Cys1 5 10415PRTArtificialNC2-1 peptide 4Gly
Cys Asn His Gly Phe Leu Ser Ala Asp Gln Gln Leu Ile Lys1 5 10
15516PRTArtificialNC2-2 5Cys Lys Gly Glu Gln Gly Asp Gln Gly Pro
Arg Met Val Phe Xaa Lys1 5 10 15615PRTArtificialNC3 peptide 6Asp
Tyr Asn Gly Asn Leu His Glu Ala Leu Gln Arg Ile Thr Cys1 5 10
15714PRTHomo sapiens 7Leu Gly Pro Asp Gly Leu Pro Met Pro Gly Cys
Trp Gln Lys1 5 10814PRTHomo sapiens 8Ile Asn His Gly Phe Leu Ser
Ala Asp Gln Gln Leu Ile Lys1 5 10914PRTHomo
sapiensMISC_FEATURE(8)..(8)Xaa at position 8 is hydroxyproline 9Gly
Glu Gln Gly Asp Gln Gly Xaa Arg Met Val Phe Pro Lys1 5
101018PRTHomo sapiens 10Asp Gln Gly Pro Arg Met Val Phe Pro Lys Ile
Asn His Gly Phe Leu1 5 10 15Ser Ala1128PRTHomo sapiens 11Gly Glu
Gln Gly Asp Gln Gly Pro Arg Met Val Phe Pro Lys Ile Asn1 5 10 15His
Gly Phe Leu Ser Ala Asp Gln Gln Leu Ile Lys 20
251226DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 12aarggngarc arggngayca rggncc
261326DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 13agctgctgrt cngcdgavag raabcc
261426DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 14agctgctgrt cngcrctvag raabcc
261528DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 15tagctgctgg tcggcgctga ggaagcca
281628DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 16aagggggaac agggggacca ggggccga
281728DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 17tcggaaacac catcctcggc ccctggtc
281828DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 18catggcttcc tcagcgccga ccagcagc
281928DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 19cgccgcctga ttaagggtga ccaaggac
282028DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 20aagagggcca cctggggaca cagggaaa
282128DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 21acccttgggg ccgttctctc cagcgtct
282228DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 22caccttgttc tccaggttct cccttagg
282328DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 23gaataccagg acctaaggga gaacctgg
282428DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 24ggccccaagg gtgacacagg cgaaaagg
282528DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 25ccctcctttc cctgcgtgct tcttcagc
282628DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 26tctcggcttc gcttcccacc ctctacac
282728DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 27ggagattctg gaatgccggg tccacagg
282828DNAArtificialdesigned oligonucleotide primer to amplify human
CLAC-P cDNA fragment 28cttctatcat aggcccacca ggcccacc
28296PRTArtificialdesigned to produce antibody Pyrog 29Xaa Ala Pro
Ser Glu Cys1 53028DNAArtificialdesigned oligonucleotide primer to
amplify mouse CLAC-P cDNA fragment 30gggatcaagg agccactaag atcataga
283128DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 31gggcctatga tagaaggacc ctgtggac
283227DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 32ctacaacggc aacctccacg aagcctt
273322DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 33tctcccttta tccccggaag tc
223428DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 34cgaatatatg gctaaaataa gaacggtc
283527DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 35ctggcaaacc ggtgtctcct ttctctc
273628DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 36acggtcaggg aggcaccttt agagtgca
283728DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 37ctctcctttt actccattgg cacccggc
283828DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 38acggtcaggg aggaagcttt agagtgca
283928DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 39tcaactccgg ggatccctgg agagcctt
284028DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 40gggaccattt tctcgagcat ctcccttt
284127DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 41aaaatggtcc caaaggtgat acaggag
274228DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 42tgcactctaa aggtgcctcc ctgaccgt
284328DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 43gaccgttctt attttagcca tatattcg
284428DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 44tggtaacctc catgaggcct tacagaga
284527DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 45gagagaaagg agacaccggt ttgccag
274626DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 46ggctggatgc tccttgccaa ttggga
264727DNAArtificialdesigned oligonucleotide primer to amplify mouse
CLAC-P cDNA fragment 47tgggacctga tgggttacct atgcctg 27482298DNAMus
musculus 48cccggcgcca cacagtcccc ggccggaggg tgcttttcac tcctagctgg
aaggggagaa 60agaatctgga ggacggtcgg tccacgcctg ctgatccgga cgccgagcca
cgcgcaggtc 120catctctaag cccgggctcc gactctacca actagttgtg
cagccgcagg gactgaactt 180tggaggaacc gacccttcct ctcattctaa
gattactgga ggagatagaa ggtggaaggc 240gtagcggagg ccagcgaccc
cgccacaatg ttggtgaaga agcttgcagg gaaaggaggg 300ggacgagagt
ctggatcaga agatccgcgc cccttgggac agcgttgtgc cggcaccatg
360ccctcgtgca cggccctggc gaccctcttg tcagtggttg ctgtggcttt
ctgtttttat 420cttggggtga aaaccaacga cctccaggcg aggattgttg
ctcttgaatc tgctaaaggg 480accccttcct tccatccgct gtctgacacc
gtggatgagc tgaaggcaat ggttcaggag 540aaagtggagc gtctcttggc
tcagaaatcc tacgaatata tggctaaaat aagaacggtc 600agggaggcac
ctttagagtg caactgccca gcaggtcctc cagggaaacg agggaagaga
660ggccgaagag gagaatctgg tcctcctggt cagcctggtc ctcagggccc
tcctggtcca 720aaaggtgata agggagaaca aggtgatcag ggacctcgga
tggtgtttcc taaaatcaat 780cacggctttc tctctgctga tcagcagctc
attaaacgcc ggctgattaa gggtgaccaa 840ggacaggcag ggcctccagg
acctccaggc cctcctggtc caagaggccc acctggggac 900acaggaaagg
acggcccccg aggaatgcca ggagtacctg gtgaaccagg aaaaccagga
960gaacaaggct tgatgggacc tctggggcct ccaggacaaa agggttccat
tggagcacct 1020gggaccccag gcatggatgg gcaaaagggt gagcctggat
cacctggagc agccgggcag 1080agtggactac caggacctaa gggagaacct
ggaaaagaag gagaaaaggg agatgctgga 1140gaaaatggtc ccaaaggtga
tacaggagaa aagggtgacc ctggatcatc tgctgcagga 1200attaagggag
aacctggaga atctggccgc ccggggcaga agggtgaacc agggctgcct
1260gggctgcctg gacttccggg aataaaggga gaaccaggct tcattggtcc
tcaaggagaa 1320ccagggttac cagggctacc aggaacaaaa ggtgatcgtg
gggaggcggg gcctcctgga 1380agaggtgaac gaggagatcc tggagccccg
gggccaaagg ggaagcaagg tgaatcagga 1440gctagaggcc cgaaggggtc
aaagggtgat cgtggagaca aaggagactc tggcgctctg 1500ggaccacggg
gtccacctgg acaaaagggg gatccaggag ccacagagat catagactac
1560aatggcaacc tccatgaggc cttacagaga attaccacct taactgtcac
gggcccccct 1620ggacctcctg gacctcaagg actacaaggg ccaaagggtg
agcaaggctc tccaggaatc 1680cccggagttg atggagaaca gggactcaaa
ggctccaagg gagacatggg ggacccaggt 1740gtgccaggtg aaaaaggagg
actgggactt cctggattgc cgggtgccaa tggagtaaaa 1800ggagagaaag
gagacaccgg tttgccaggt cctcaggggc cttctatcat aggcccacca
1860ggccctccag gtccccatgg cccacctggt cccatggggc cccatggact
tcctggacca 1920aagggagcat ctggcttaga cggaaagcca ggatcccggg
gtgcagatgg tcctatagga 1980ccccacggcc ctgcaggacc caaaggagaa
agaggagaga aaggagctat gggagagcct 2040ggacccagag ggccctatgg
gctgcctggc aaagatggag aacctggtct tgatggcttc 2100cctggtcctc
gaggcgagaa gggtgacctg ggagaaaagg gagaaaaggg attccgtggc
2160gttaaggggg aaaaggggga gccaggccag cctggcctgg atgggctgga
tgctccttgc 2220caattgggac ctgatgggtt acctatgcct ggctgctggc
aaaagtgatg aatctaacct
2280tccgagcatg aagttgtg 229849666PRTMus musculus 49Met Leu Val Lys
Lys Leu Ala Gly Lys Gly Gly Gly Arg Glu Ser Gly1 5 10 15Ser Glu Asp
Pro Arg Pro Leu Gly Gln Arg Cys Ala Gly Thr Met Pro 20 25 30Ser Cys
Thr Ala Leu Ala Thr Leu Leu Ser Val Val Ala Val Ala Phe 35 40 45Cys
Phe Tyr Leu Gly Val Lys Thr Asn Asp Leu Gln Ala Arg Ile Val 50 55
60Ala Leu Glu Ser Ala Lys Gly Thr Pro Ser Phe His Pro Leu Ser Asp65
70 75 80Thr Val Asp Glu Leu Lys Ala Met Val Gln Glu Lys Val Glu Arg
Leu 85 90 95Leu Ala Gln Lys Ser Tyr Glu Tyr Met Ala Lys Ile Arg Thr
Val Arg 100 105 110Glu Ala Pro Leu Glu Cys Asn Cys Pro Ala Gly Pro
Pro Gly Lys Arg 115 120 125Gly Lys Arg Gly Arg Arg Gly Glu Ser Gly
Pro Pro Gly Gln Pro Gly 130 135 140Pro Gln Gly Pro Pro Gly Pro Lys
Gly Asp Lys Gly Glu Gln Gly Asp145 150 155 160Gln Gly Pro Arg Met
Val Phe Pro Lys Ile Asn His Gly Phe Leu Ser 165 170 175Ala Asp Gln
Gln Leu Ile Lys Arg Arg Leu Ile Lys Gly Asp Gln Gly 180 185 190Gln
Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Arg Gly Pro 195 200
205Pro Gly Asp Thr Gly Lys Asp Gly Pro Arg Gly Met Pro Gly Val Pro
210 215 220Gly Glu Pro Gly Lys Pro Gly Glu Gln Gly Leu Met Gly Pro
Leu Gly225 230 235 240Pro Pro Gly Gln Lys Gly Ser Ile Gly Ala Pro
Gly Thr Pro Gly Met 245 250 255Asp Gly Gln Lys Gly Glu Pro Gly Ser
Pro Gly Ala Ala Gly Gln Ser 260 265 270Gly Leu Pro Gly Pro Lys Gly
Glu Pro Gly Lys Glu Gly Glu Lys Gly 275 280 285Asp Ala Gly Glu Asn
Gly Pro Lys Gly Asp Thr Gly Glu Lys Gly Asp 290 295 300Pro Gly Ser
Ser Ala Ala Gly Ile Lys Gly Glu Pro Gly Glu Ser Gly305 310 315
320Arg Pro Gly Gln Lys Gly Glu Pro Gly Leu Pro Gly Leu Pro Gly Leu
325 330 335Pro Gly Ile Lys Gly Glu Pro Gly Phe Ile Gly Pro Gln Gly
Glu Pro 340 345 350Gly Leu Pro Gly Leu Pro Gly Thr Lys Gly Asp Arg
Gly Glu Ala Gly 355 360 365Pro Pro Gly Arg Gly Glu Arg Gly Asp Pro
Gly Ala Pro Gly Pro Lys 370 375 380Gly Lys Gln Gly Glu Ser Gly Ala
Arg Gly Pro Lys Gly Ser Lys Gly385 390 395 400Asp Arg Gly Asp Lys
Gly Asp Ser Gly Ala Leu Gly Pro Arg Gly Pro 405 410 415Pro Gly Gln
Lys Gly Asp Pro Gly Ala Thr Glu Ile Ile Asp Tyr Asn 420 425 430Gly
Asn Leu His Glu Ala Leu Gln Arg Ile Thr Thr Leu Thr Val Thr 435 440
445Gly Pro Pro Gly Pro Pro Gly Pro Gln Gly Leu Gln Gly Pro Lys Gly
450 455 460Glu Gln Gly Ser Pro Gly Ile Pro Gly Val Asp Gly Glu Gln
Gly Leu465 470 475 480Lys Gly Ser Lys Gly Asp Met Gly Asp Pro Gly
Val Pro Gly Glu Lys 485 490 495Gly Gly Leu Gly Leu Pro Gly Leu Pro
Gly Ala Asn Gly Val Lys Gly 500 505 510Glu Lys Gly Asp Thr Gly Leu
Pro Gly Pro Gln Gly Pro Ser Ile Ile 515 520 525Gly Pro Pro Gly Pro
Pro Gly Pro His Gly Pro Pro Gly Pro Met Gly 530 535 540Pro His Gly
Leu Pro Gly Pro Lys Gly Ala Ser Gly Leu Asp Gly Lys545 550 555
560Pro Gly Ser Arg Gly Ala Asp Gly Pro Ile Gly Pro His Gly Pro Ala
565 570 575Gly Pro Lys Gly Glu Arg Gly Glu Lys Gly Ala Met Gly Glu
Pro Gly 580 585 590Pro Arg Gly Pro Tyr Gly Leu Pro Gly Lys Asp Gly
Glu Pro Gly Leu 595 600 605Asp Gly Phe Pro Gly Pro Arg Gly Glu Lys
Gly Asp Leu Gly Glu Lys 610 615 620Gly Glu Lys Gly Phe Arg Gly Val
Lys Gly Glu Lys Gly Glu Pro Gly625 630 635 640Gln Pro Gly Leu Asp
Gly Leu Asp Ala Pro Cys Gln Leu Gly Pro Asp 645 650 655Gly Leu Pro
Met Pro Gly Cys Trp Gln Lys 660 66550245DNAMus musculus
50acagagaatt accaccttaa ctgtcacggg cccccctgga cctcctggac ctcaaggact
60acaagggcca aagggtgagc aaggctctcc aggaatcccc ggagttgatg gagaacaggg
120actcaaaggc tccaagggag acatggggga cccaggtgtg ccaggtgaaa
aaggaggact 180gggacttcct ggattgccgg gtgccaatgg agtaaaagga
gagaaaggag acaccggttt 240gccag 2455173DNAMus musculus 51agaaatccta
cgaatatatg gctaaaataa gaacggtcag ggaggcacct ttagagtgca 60actgcccagc
agg 7352502DNAMus musculus 52actgcccagc aggtcctcca gggaaacgag
ggaagagagg ccgaagagga gaatctggtc 60ctcctggtca gcctggtcct cagggccctc
ctggtccaaa aggtgataag ggagaacaag 120gtgatcaggg acctcggatg
gtgtttccta aaatcaatca cggctttctc tctgctgatc 180agcagctcat
taaacgccgg ctgattaagg gtgaccaagg acaggcaggg cctccaggac
240ctccaggccc tcctggtcca agaggcccac ctggggacac aggaaaggac
ggcccccgag 300gaatgccagg agtacctggt gaaccaggaa aaccaggaga
acaaggcttg atgggacctc 360tggggcctcc aggacaaaag ggttccattg
gagcacctgg gaccccaggc atggatgggc 420aaaagggtga gcctggatca
cctggagcag ccgggcagag tggactacca ggacctaagg 480gagaacctgg
aaaagaagga ga 50253495DNAMus musculus 53aaaagggtga ccctggatca
tctgctgcag gaattaaggg agaacctgga gaatctggcc 60gcccggggca gaagggtgaa
ccagggctgc ctgggctgcc tggacttccg ggaataaagg 120gagaaccagg
cttcattggt cctcaaggag aaccagggtt accagggcta ccaggaacaa
180aaggtgatcg tggggaggcg gggcctcctg gaagaggtga acgaggagat
cctggagccc 240cggggccaaa ggggaagcaa ggtgaatcag gagctagagg
cccgaagggg tcaaagggtg 300atcgtggaga caaaggagac tctggcgctc
tgggaccacg gggtccacct ggacaaaagg 360gggatccagg agccacagag
atcatagact acaatggcaa cctccatgag gccttacaga 420gaattaccac
cttaactgtc acgggccccc ctggacctcc tggacctcaa ggactacaag
480ggccaaaggg tgagc 49554572DNAMus musculus 54cccggcgcca cacagtcccc
ggccggaggg tgcttttcac tcctagctgg aaggggagaa 60agaatctgga ggacggtcgg
tccacgcctg ctgatccgga cgccgagcca cgcgcaggtc 120catctctaag
cccgggctcc gactctacca actagttgtg cagccgcagg gactgaactt
180tggaggaacc gacccttcct ctcattctaa gattactgga ggagatagaa
ggtggaaggc 240gtagcggagg ccagcgaccc cgccacaatg ttggtgaaga
agcttgcagg gaaaggaggg 300ggacgagagt ctggatcaga agatccgcgc
cccttgggac agcgttgtgc cggcaccatg 360ccctcgtgca cggccctggc
gaccctcttg tcagtggttg ctgtggcttt ctgtttttat 420cttggggtga
aaaccaacga cctccaggcg aggattgttg ctcttgaatc tgctaaaggg
480accccttcct tccatccgct gtctgacacc gtggatgagc tgaaggcaat
ggttcaggag 540aaagtggagc gtctcttggc tcagaaatcc ta 57255427DNAMus
musculus 55gtcctcaggg gccttctatc ataggcccac caggccctcc aggtccccat
ggcccacctg 60gtcccatggg gccccatgga cttcctggac caaagggagc atctggctta
gacggaaagc 120caggatcccg gggtgcagat ggtcctatag gaccccacgg
ccctgcagga cccaaaggag 180aaagaggaga gaaaggagct atgggagagc
ctggacccag agggccctat gggctgcctg 240gcaaagatgg agaacctggt
cttgatggct tccctggtcc tcgaggcgag aagggtgacc 300tgggagaaaa
gggagaaaag ggattccgtg gcgttaaggg ggaaaagggg gagccaggcc
360agcctggcct ggatgggctg gatgctcctt gccaattggg acctgatggg
ttacctatgc 420ctggctg 4275647DNAMus musculus 56gctgctggca
aaagtgatga atctaacctt ccgagcatga agttgtg 47
* * * * *